UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________

FORM 10-Q

______________________________



ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~March~~December 31, 2017



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

001-36587

(Commission File Number)

_____________________________

Catalent, Inc.

(Exact name of registrant as specified in its charter)

_____________________________



Delaware		20-8737688
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

14 Schoolhouse Road, Somerset, NJ		08873
(Address of principal executive offices)		(Zip code)

(732) 537-6200

Registrant's telephone number, including area code

______________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer x		Accelerated filer ¨
Non-accelerated filer ¨	(Do not check if a smaller reporting company)	Smaller reporting company ¨
		Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

On ~~April 28, 2017,~~February 2, 2018, there were ~~124,960,202~~133,318,679 shares of the Registrant's common stock, par value $0.01 per share, issued and outstanding.

Table of Contents

CATALENT, INC. and Subsidiaries

INDEX TO FORM 10-Q

For the Three and ~~Nine~~Six Months Ended ~~March~~December 31, 2017



Item		Page

Part I.	Financial Information

Item 1.	Financial Statements (unaudited)	56

	Consolidated Statements of Operations for the Three and ~~Nine~~Six Months Ended ~~March~~December 31, 2017 and ~~March~~December 31, 2016	56

	Consolidated Statements of Comprehensive Income/(Loss) for the Three and ~~Nine~~Six Months Ended ~~March~~December 31, 2017 and ~~March~~December 31, 2016	67

	Consolidated Balance Sheets as of ~~March~~December 31, 2017 and June 30, ~~2016~~2017	78

	Consolidated Statement of Changes in Shareholders' Equity/(Deficit) as of ~~March~~December 31, 2017	89

	Consolidated Statements of Cash Flows for the ~~Nine~~Six Months Ended ~~March~~December 31, 2017 and ~~March~~December 31, 2016	910

	Notes to Unaudited Consolidated Financial Statements	1011

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2729

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4346

Item 4.	Controls and Procedures	4447

Part II.	Other Information	4548

Item 1.	Legal Proceedings	4548

Item 1A.	Risk Factors	4548

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4549

Item 3.	Defaults Upon Senior Securities	4549

Item 4.	Mine Safety Disclosures	4549

Item 5.	Other Information	4649

Item 6.	Exhibits	4649

Signatures		4750

Table of Contents

Special Note Regarding Forward-Looking Statements

In addition to historical information, this Quarterly Report on Form 10-Q may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words.

These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statement is subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.

Some of the factors that may cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements include, but are not limited to, those described under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, ~~2016~~2017 and the following:

We participate in a highly competitive market, and increased competition may adversely affect our business.

The demand for our offerings depends in part on our customers’ research and development and the clinical and market success of their products. Our business, financial condition and results of operations may be harmed if our customers spend less on, or are less successful in, these activities.

We are subject to product and other liability risks that could adversely affect our results of operations, financial condition, liquidity, and cash flows.

Failure to comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition or result in claims from customers.

Failure to provide quality offerings to our customers could have an adverse effect on our business and subject us to regulatory actions or costly litigation.

The services and offerings we provide are highly exacting and complex, and if we encounter problems providing the services or support required, our business could suffer.

Our global operations are subject to economic, political, and regulatory risks, including the risks of changing regulatory standards or changing interpretations of existing standards, that could affect the profitability of our operations or require costly changes to our procedures.

The referendum in the ~~U.K.~~United Kingdom (the "U.K.") and resulting decision of the U.K. government to consider exiting from the European Union could have future adverse effects on our revenues and costs, and therefore our profitability.

If we do not enhance our existing or introduce new technology or service offerings in a timely manner, our offerings may become obsolete ~~or uncompetitive~~ over time, customers may not buy our offerings, and our revenue and profitability may decline.

We and our customers depend on patents, copyrights, trademarks, trade secrets, and other forms of intellectual property protections, but these protections may not be adequate.

Our future results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials.

Changes in market access or healthcare reimbursement for our customers’ products in the United States or internationally, including the possible repeal or replacement of the Affordable Care Act in the United States, could adversely affect our results of operations and financial condition by affecting demand for our offerings.

Table of Contents

As a global enterprise, fluctuations in the exchange rate of the U.S. dollar against foreign currencies could have a material adverse effect on our financial performance and results of operations.

The impact to our business of recently enacted U.S. tax legislation could differ materially from our current estimates.

Tax ~~legislation~~legislative or regulatory initiatives or challenges to our tax positions could adversely affect our results of operations and financial condition.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Changes to the estimated future profitability of the business may require that we establish an additional valuation allowance against all or some portion of our net U.S. deferred tax assets.

We are dependent on key personnel.

We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counter-parties, so the risks generally associated with information and communications systems could adversely affect our results of operations. We are continuously working to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cyber security risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises of data security.

We engage, from time to time, in acquisitions and other transactions that may complement or expand our business or divest of non-strategic businesses or assets. We may not be able to complete such transactions, and such transactions, if executed, pose significant risks, including risks relating to our ability to successfully and efficiently integrate acquisitions and realize anticipated benefits therefrom. The failure to execute or realize the full benefits from any such transaction could have a negative effect on our operations.

Our offerings or our customers’ products may infringe on the intellectual property rights of third parties.

We are subject to environmental, health, and safety laws and regulations, which could increase our costs and restrict our operations in the future.

We are subject to labor and employment laws and regulations, which could increase our costs and restrict our operations in the future.

Certain of our pension plans are underfunded, and additional cash contributions we may make to increase the funding level will reduce the cash available for our business, ~~or to discharge~~such as the payment of our ~~financial obligations.~~interest expense.

Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or in our industry, ~~or to deploy capital to grow our business,~~ expose us to interest-rate risk to the extent of our variable rate debt and prevent us from meeting our obligations under our indebtedness.

We caution you that the risks, uncertainties and other factors referenced above may not contain all of the risks, uncertainties, and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of this report or as of the date they were made and we undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Social Media

We use our website (www.catalent.com), our corporate Facebook page (https://www.facebook.com/CatalentPharmaSolutions), and our corporate Twitter account (@catalentpharma) as channels for the distribution of

Table of Contents

information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, Securities and Exchange Commission ("SEC") filings and public conference calls and webcasts. The contents of our website and social media channels are not, however, a part of this report.

Table of Contents

PART I. FINANCIAL INFORMATION


Item 1.	FINANCIAL STATEMENTS

Catalent, Inc. and Subsidiaries

Consolidated Statements of Operations

(Unaudited; Dollars in millions, except per share data)

Three Months Ended
March 31, Nine Months Ended
March 31,
2017 2016 2017 2016
Net revenue $ 532.6
$ 438.0
$ 1,458.5
$ 1,315.9
Cost of sales 365.2
311.8
1,019.1
916.1
Gross margin 167.4
126.2
439.4
399.8
Selling, general and administrative expenses 100.9
93.4
295.3
268.6
Impairment charges and (gain)/loss on sale of assets 1.8
(0.3 ) 2.3
0.8
Restructuring and other 0.1
1.8
4.5
3.4
Operating earnings 64.6
31.3
137.3
127.0
Interest expense, net 22.6
21.7
67.5
66.7
Other (income)/expense, net 7.3
(4.2 ) 3.4
(7.1 )
Earnings from continuing operations, before income taxes 34.7
13.8
66.4
67.4
Income tax expense 8.7
3.1
18.4
14.3
Net earnings 26.0
10.7
48.0
53.1
Less: Net (loss) attributable to noncontrolling interest, net
of tax
—
—
—
(0.3 )
Net earnings attributable to Catalent $ 26.0
$ 10.7
$ 48.0
$ 53.4

Earnings per share attributable to Catalent:
Basic
Net earnings 0.21
0.09
0.38
0.43
Diluted

Net earnings 0.21
0.09
0.38
0.42

~~The accompanying notes are an integral part of these unaudited consolidated financial statements.~~

~~Table of Contents~~

~~Catalent, Inc. and Subsidiaries~~

~~Consolidated Statements of Comprehensive Income/(Loss)~~

~~(Unaudited; Dollars in millions)~~

Three Months Ended
March 31, Nine Months Ended
March 31,
2017 2016 2017 2016
Net earnings $ 26.0
$ 10.7
$ 48.0
$ 53.1
Other comprehensive income/(loss), net of tax
Foreign currency translation adjustments 24.6
(15.9 ) (39.2 ) (82.3 )
Pension and other post-retirement adjustments 0.8
0.6
2.3
1.6
Available for sale investments 1.0
—
16.3
—
Deferred compensation —
—
—
(0.2 )
Other comprehensive income/(loss), net of tax 26.4
(15.3 ) (20.6 ) (80.9 )
Comprehensive income/(loss) 52.4
(4.6 ) 27.4
(27.8 )
Comprehensive income/(loss) attributable to
noncontrolling interest
—
—
—
(0.3 )
Comprehensive income/(loss) attributable to Catalent $ 52.4
$ (4.6 ) $ 27.4
$ (27.5 )



	Three Months Ended December 31,						Six Months Ended December 31,
	2017			2016			2017			2016
Net revenue	$	606.3		$	483.7		$	1,150.2		$	925.9
Cost of sales	418.9			335.8			822.7			653.9
Gross margin	187.4			147.9			327.5			272.0
Selling, general and administrative expenses	114.3			96.2			221.3			194.4
Impairment charges and (gain)/loss on sale of assets	4.2			0.5			4.2			0.5
Restructuring and other	0.1			3.3			1.3			4.4
Operating earnings	68.8			47.9			100.7			72.7
Interest expense, net	27.2			22.8			51.5			44.9
Other expense/(income), net	13.6			(1.8		)	19.3			(3.9		)
Earnings from continuing operations, before income taxes	28.0			26.9			29.9			31.7
Income tax expense	49.9			9.5			48.0			9.7
Net earnings/(loss)	$	(21.9	)	$	17.4		$	(18.1	)	$	22.0


Earnings per share:
Basic
Net earnings/(loss)	$	(0.16	)	$	0.14		$	(0.14	)	$	0.18
Diluted
Net earnings/(loss)	$	(0.16	)	$	0.14		$	(0.14	)	$	0.17

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Catalent, Inc. and Subsidiaries

Consolidated ~~Balance Sheets~~Statements of Comprehensive Income/(Loss)

(Unaudited; Dollars in ~~millions, except per share data)~~millions)

March 31,
2017 June 30,
2016
ASSETS
Current assets:
Cash and cash equivalents $ 241.2
$ 131.6
Trade receivables, net 402.6
414.8
Inventories 193.9
154.8
Prepaid expenses and other 90.7
89.0
Total current assets 928.4
790.2
Property, plant, and equipment, net 968.9
905.8
Other assets:
Goodwill 1,030.6
996.5
Other intangibles, net 282.6
294.0
Deferred income taxes 53.0
37.5
Other 21.7
67.1
Total assets $ 3,285.2
$ 3,091.1

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term obligations and other short-term borrowings $ 23.7
$ 27.7
Accounts payable 137.6
143.7
Other accrued liabilities 228.8
219.8
Total current liabilities 390.1
391.2
Long-term obligations, less current portion 2,025.3
1,832.8
Pension liability 141.5
151.0
Deferred income taxes 43.0
41.4
Other liabilities 42.6
38.8
Commitment and contingencies (see Note 12)

Shareholders' equity/(deficit):
Common stock $0.01 par value; 1.0 billion and 1.0 billion shares authorized on March 31, 2017 and June 30, 2016, 124,927,160 and 124,712,240 issued and outstanding on March 31, 2017 and June 30, 2016, respectively. 1.2
1.2
Preferred stock $0.01 par value; 100 million and 100 million authorized on March 31, 2017 and June 30, 2016, respectively, 0 issued and outstanding on March 31, 2017 and June 30, 2016. —
—
Additional paid in capital 1,990.1
1,976.5
Accumulated deficit (1,022.3 ) (1,036.1 )
Accumulated other comprehensive income/(loss) (326.3 ) (305.7 )
Total shareholders' equity 642.7
635.9
Total liabilities and shareholders' equity $ 3,285.2
$ 3,091.1



	Three Months Ended December 31,						Six Months Ended December 31,
	2017			2016			2017			2016
Net earnings/(loss)	$	(21.9	)	$	17.4		$	(18.1	)	$	22.0
Other comprehensive income/(loss), net of tax
Foreign currency translation adjustments	(13.4		)	(64.4		)	24.7			(63.8		)
Pension and other post-retirement adjustments	0.5			0.7			0.9			1.5
Available for sale investments	(3.0		)	15.3			(6.4		)	15.3
Other comprehensive income/(loss), net of tax	(15.9		)	(48.4		)	19.2			(47.0		)
Comprehensive income/(loss)	$	(37.8	)	$	(31.0	)	$	1.1		$	(25.0	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Catalent, Inc. and Subsidiaries

Consolidated ~~Statement of Changes in Shareholders' Equity/(Deficit)~~Balance Sheets

(Unaudited; Dollars in millions, except share ~~counts in thousands)~~and per share data)

Shares of Common Stock
Common
Stock
Additional
Paid in
Capital
Accumulated
Deficit

Accumulated
Other
Comprehensive
Income/(Loss)

Total
Shareholders'
Equity/ (Deficit)
Balance at June 30, 2016 124,712.2
$ 1.2
$ 1,976.5
$ (1,036.1 ) $ (305.7 ) $ 635.9
Cumulative effect of a change in
     accounting for income taxes (Note 1)
(34.2 ) (34.2 )
Share issuances related to equity based
     compensation
215.0

Equity compensation 16.4
16.4
Cash paid, in lieu of equity, for tax
     withholding
(2.8 ) (2.8 )
Net earnings/(loss) 48.0
48.0
Other comprehensive income/(loss), net
     tax
(20.6 ) (20.6 )
Balance at March 31, 2017 124,927.2
$ 1.2
$ 1,990.1
$ (1,022.3 ) $ (326.3 ) $ 642.7



	December 31, 2017			June 30, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	329.5		$	288.3
Trade receivables, net	427.9			488.8
Inventories	212.7			184.9
Prepaid expenses and other	105.4			97.8
Total current assets	1,075.5			1,059.8
Property, plant, and equipment, net	1,256.2			995.9
Other assets:
Goodwill	1,408.3			1,044.1
Other intangibles, net	582.0			273.1
Deferred income taxes	34.3			53.9
Other	30.8			27.5
Total assets	$	4,387.1		$	3,454.3

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term obligations and other short-term borrowings	$	69.9		$	24.6
Accounts payable	164.3			163.2
Other accrued liabilities	249.8			281.2
Total current liabilities	484.0			469.0
Long-term obligations, less current portion	2,672.5			2,055.1
Pension liability	127.3			129.5
Deferred income taxes	40.7			31.7
Other liabilities	57.1			45.5
Commitment and contingencies (see Note 13)

Shareholders' equity/(deficit):
Common stock $0.01 par value; 1.0 billion shares authorized on December 31, 2017 and June 30, 2017, 133,318,039 and 125,049,867 issued and outstanding on December 31, 2017 and June 30, 2017, respectively.	1.3			1.3
Preferred stock $0.01 par value; 100 million authorized on December 31, 2017 and June 30, 2017, 0 issued and outstanding on December 31, 2017 and June 30, 2017.	—			—
Additional paid in capital	2,272.9			1,992.0
Accumulated deficit	(973.8		)	(955.7		)
Accumulated other comprehensive income/(loss)	(294.9		)	(314.1		)
Total shareholders' equity	1,005.5			723.5
Total liabilities and shareholders' equity	$	4,387.1		$	3,454.3

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Catalent, Inc. and Subsidiaries

Consolidated Statement of Changes in Shareholders' Equity/(Deficit)

(Unaudited; Dollars in millions, except share data in thousands)



	Shares of Common Stock	Common Stock		Additional Paid in Capital			Accumulated Deficit			Accumulated Other Comprehensive Income/(Loss)			Total Shareholders' Equity/ (Deficit)
Balance at June 30, 2017	125,049.9	$	1.3	$	1,992.0		$	(955.7	)	$	(314.1	)	$	723.5
Equity offering, sale of common stock	7,354.2	—		277.8									277.8
Share issuances related to equity-based compensation	913.9												—
Equity compensation				15.5									15.5
Cash paid, in lieu of equity, for tax withholding				(12.4		)							(12.4		)
Net earnings/(loss)							(18.1		)				(18.1		)
Other comprehensive income/(loss), net tax										19.2			19.2
Balance at December 31, 2017	133,318.0	$	1.3	$	2,272.9		$	(973.8	)	$	(294.9	)	$	1,005.5

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Catalent, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited; Dollars in millions)


	Nine Months Ended March 31,						Six Months Ended December 31,
	2017			2016			2017			2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	$	48.0		$	53.1
Net earnings/(loss)							$	(18.1	)	$	22.0
Adjustments to reconcile earnings from continued operations to net cash from operations:
Depreciation and amortization	107.8			105.5			85.8			71.3
Non-cash foreign currency transaction (gain)/loss, net	5.7			(5.2		)	7.1			(3.4		)
Amortization and write off of debt financing costs	5.6			3.4			2.5			4.3
Asset impairments and (gain)/loss on sale of assets	2.3			0.8			4.2			0.5
Reclassification of financing fees paid							11.8			—
Equity compensation	16.4			8.8			15.5			11.8
Provision/(benefit) for deferred income taxes	0.8			(0.7		)	35.6			0.9
Provision for bad debts and inventory	5.6			8.2			3.5			3.3
Change in operating assets and liabilities:
Decrease/(increase) in trade receivables	26.3			20.7			104.6			41.4
Decrease/(increase) in inventories	(20.2		)	(43.7		)	—			(17.9		)
Increase/(decrease) in accounts payable	(12.4		)	6.6			(0.4		)	(14.6		)
Other assets/accrued liabilities, net - current and non-current	13.4			(36.1		)	(76.1		)	(23.6		)
Net cash provided by operating activities	199.3			121.4			176.0			96.0
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment and other productive assets	(87.8		)	(107.8		)	(82.9		)	(54.1		)
Proceeds from sale of property and equipment	0.7			—			1.8			1.3
Proceeds from sale of subsidiaries							3.4			—
Payment for acquisitions, net of cash acquired	(169.9		)	—			(748.0		)	(85.7		)
Net cash (used in)/provided by investing activities	(257.0		)	(107.8		)
Net cash (used in) investing activities							(825.7		)	(138.5		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net change in other borrowings	(5.9		)	0.6			(0.6		)	(5.6		)
Proceeds from borrowing, net	397.4			—			442.6			397.4
Payments related to long-term obligations	(213.9		)	(13.9		)	(9.4		)	(209.2		)
Financing fees paid	(6.4		)	—			(15.6		)	(6.4		)
Purchase of redeemable noncontrolling interest shares	—			(5.8		)
Proceeds from sale of common stock, net							277.8			—
Cash paid, in lieu of equity, for tax withholding obligations	(2.8		)	(8.0		)	(12.4		)	(0.5		)
Net cash provided by/(used in) financing activities	168.4			(27.1		)
Net cash provided by financing activities							682.4			175.7
Effect of foreign currency on cash	(1.1		)	(3.9		)	8.5			(9.0		)
NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS	109.6			(17.4		)	41.2			124.2
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	131.6			151.3			288.3			131.6
CASH AND EQUIVALENTS AT END OF PERIOD	$	241.2		$	133.9		$	329.5		$	255.8
SUPPLEMENTARY CASH FLOW INFORMATION:
Interest paid	$	54.8		$	62.6		$	41.5		$	39.4
Income taxes paid, net	$	25.8		$	30.2		$	8.0		$	19.7

The accompanying notes are an integral part of these unaudited consolidated financial statements.

910

Table of Contents

Catalent, Inc. and Subsidiaries

Notes to Unaudited Consolidated Financial Statements


1.	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business

Catalent, Inc. (“Catalent” or the “Company”) directly and wholly owns PTS Intermediate Holdings LLC (“Intermediate Holdings”). Intermediate Holdings directly and wholly owns Catalent Pharma Solutions, Inc. (“Operating Company”). The financial results of Catalent are comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis.

On July 31, 2014, the Company commenced an initial public offering of its common stock (the “IPO”) and its common stock began trading on the New York Stock Exchange (the “NYSE”) under the symbol “CTLT.”

On March 9, 2015, an affiliate of The Blackstone Group, L.P. that owned shares in the Company (“Blackstone”), Genstar Capital and Aisling Capital (collectively, the “selling stockholders”) completed a secondary offering of 27.3 million shares of the Company’s common stock, including 3.6 million shares sold pursuant to an over-allotment option, at a price of $29.50 per share before underwriting discounts and commissions. On June 2, 2015, the selling stockholders completed an additional secondary offering of 16.1 million shares, including 2.1 million shares sold pursuant to the over-allotment option, at a price of $29.00 per share before underwriting discounts and commissions. On June 6, 2016, the selling stockholders completed a secondary offering of 10.0 million shares of the Company's common stock at a price of $24.85 per share before underwriting discounts and commissions. On September 6, 2016, two of the selling stockholders completed a secondary offering of their remaining shares totaling approximately 19.0 million shares, at a price of $23.85 per share before underwriting discounts and commissions. The Company did not sell stock in any of the secondary offerings and did not receive any proceeds of the sales.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the ~~nine~~six months ended ~~March~~December 31, 2017 are not necessarily indicative of the results that may be expected for the year ending June 30, ~~2017~~2018. The consolidated balance sheet at June 30, ~~2016~~2017 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. For further information on the Company's accounting policies and footnotes, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, ~~2016~~2017 filed with the Securities and Exchange Commission ("SEC").

In the fourth quarter of fiscal 2016, we engaged in a business reorganization to better align our internal business unit structure with our "Follow the Molecule" strategy. Under the revised structure, we have created a Drug Delivery Solutions ("DDS") operating segment, which encompasses all of our modified release technologies; prefilled syringes and other injectable formats; blow-fill-seal unit dose development and manufacturing; biologic cell line development; analytical services; micronization technologies; and other conventional oral dose forms under a single DDS management team. Additionally, as part of the re-alignment, we have created a stand-alone Clinical Supply Services ("CSS") operating segment and management team with a sole focus on providing global clinical supply chain management services that aim to speed our customers' drugs to market. Further, as a result of the business unit re-alignment, our Softgel Technologies business now reports as a distinct operating segment. Our operating segments are the same as our reporting segments. All prior period comparative segment information has been restated to reflect the current reportable segments in accordance with ~~Accounting Standard Codification(“ASC”) 280 Segment Reporting.~~

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts.

~~Table of Contents~~

Foreign Currency Translation

The financial statements of the Company’s operations outside the U.S. are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign operations into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. The currency fluctuations related to certain long-term inter-company loans deemed to not be repayable in the foreseeable future have been recorded within cumulative translation adjustment, a component of other comprehensive income/(loss). In addition, the currency fluctuation associated with the portion of the Company’s euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income/(loss). Foreign currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the consolidated statements of operations in the other (income)/expense, net line item. Foreign currency translation gains and losses generated from inter-company loans that are long-term in nature, but may be repayable in the foreseeable future, are also recorded within the other (income)/expense, net line item on the consolidated statements of operations.

Revenue Recognition

In accordance with ~~ASC~~Accounting Standards Codification ("ASC") 605 Revenue Recognition, the Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. In cases where the Company has multiple contracts with the same customer, the Company evaluates those contracts to assess if the contracts are linked or are separate arrangements. Factors the Company considers include the timing of negotiation, interdependency with other contracts or elements and payment terms. The Company and its customers generally view each contract discussion as a separate arrangement.

Manufacturing and packaging service revenue is recognized upon delivery of the product in accordance with the terms of the contract, which specify when transfer of title and risk of loss occurs. Some of the Company’s manufacturing contracts with

Table of Contents

its customers have annual minimum purchase requirements. At the end of the contract year, revenue is recognized for the unfilled purchase obligation in accordance with the contract terms. Development service contracts generally take the form of a fee-for-service arrangement. After the Company has evidence of an arrangement, the price is determinable and there is a reasonable expectation regarding payment, the Company recognizes revenue at the point in time the service obligation is completed and accepted by the customer. Examples of output measures include a formulation report, analytical and stability testing, clinical batch production or packaging and the storage and distribution of a customer’s clinical trial material. Development service revenue is primarily driven by the Company’s ~~DDS~~Drug Delivery Solutions segment.

Arrangements containing multiple elements, including service arrangements, are accounted for in accordance with the provisions of ASC 605-25 Revenue Recognition—Multiple-Element Arrangements. The Company determines the separate units of account in accordance with ASC 605-25. If the deliverable meets the criteria of a separate unit of accounting, the arrangement consideration is allocated to each element based upon its relative selling price. In determining the best evidence of selling price of a unit of account, the Company utilizes vendor-specific objective evidence (“VSOE”), which is the price the Company charges when the deliverable is sold separately. When VSOE is not available, management uses relevant third-party evidence (“TPE”) of selling price, if available. When neither VSOE nor TPE of selling price exists, management uses its best estimate of selling price.

Goodwill

The Company accounts for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350 Goodwill, Intangible and Other Assets. Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. The Company's annual goodwill impairment test was conducted as of April 1, ~~2016.~~2017. The Company assesses goodwill for possible impairment by comparing the carrying value of its reporting units to their fair values. The Company determines the fair value of its reporting units utilizing estimated future discounted cash flows and incorporates assumptions that it believes marketplace participants would utilize. In addition, the Company uses comparative market information and other factors to corroborate the discounted cash flow results.

Property and Equipment and Other Definite Lived Intangible Assets

Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following ranges of useful lives for its property and equipment categories: buildings and improvements — 5 to 50 years; machinery and equipment — 3 to 10 years; and furniture and fixtures — 3 to 7 years. Depreciation expense was $~~25.5~~30.7 million and ~~$74.7~~$58.3 million for the three and ~~nine~~six months ended ~~March~~December 31, 2017, respectively, and $~~23.4~~24.4 million and ~~$70.5~~$49.2 million for the three and ~~nine~~six months ended ~~March~~December 31, 2016, respectively. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest was immaterial for all periods presented.

~~Table of Contents~~

Intangible assets with finite lives, primarily including customer relationships, ~~and~~ patents and trademarks ~~continue to be~~are amortized over their useful lives. The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360 Property, Plant and Equipment. This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arm's length transactions. Impairment charges related to definite lived intangible assets and property, plant and equipment were not material for the three and six months ended December 31, 2017 and 2016.

Research and Development Costs

The Company expenses research and development costs as incurred. Costs incurred in connection with the development of new offerings and manufacturing process improvements are recorded within selling, general and administrative expenses. Such research and development costs included in selling, general and administrative expenses amounted to $~~2.3~~1.5 million and ~~$5.3~~$3.3 million for the three and ~~nine~~six months ended ~~March~~December 31, 2017, respectively, and $~~2.1~~1.5 million and ~~$5.8~~$3.0 million for the three and ~~nine~~six months ended ~~March~~December 31, 2016, respectively. Costs incurred in connection with research and development services the Company provides to customers and services performed in support of the commercial manufacturing process for customers are recorded within cost of sales. Such research and development costs included in cost of sales amounted to $~~11.5~~12.4 million and ~~$32.8~~$22.4 million for the three and ~~nine~~six months ended ~~March~~December 31, 2017, respectively, and $~~11.7~~11.0 million and ~~$35.8~~$21.3 million for the three and ~~nine~~six months ended ~~March~~December 31, 2016, respectively.

Table of Contents

Earnings / (Loss) Per Share

The Company reports net earnings/(loss) per share ~~pursuant to~~in accordance with ASC 260 Earnings per Share. Under ASC 260, basic earnings per share, which excludes dilution, is computed by dividing net earnings or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution caused by securities that could be exercised or converted into common shares, and is computed by dividing net earnings or loss available to common stockholders by the weighted average of common shares outstanding plus the dilutive potential common shares. Diluted earnings per share includes in-the-money stock options, restricted stock units, and unvested restricted stock using the treasury stock method. During a loss period, the assumed exercise of in-the-money stock options has an anti-dilutive effect, and, therefore, these instruments are excluded from the computation of diluted earnings per share.

Equity-Based Compensation

The Company accounts for its equity-based compensation awards pursuant to ASC 718 Compensation—Stock Compensation. ASC 718 requires companies to recognize compensation expense using a fair value based method for costs related to share-based payments including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards, ~~that are expected to vest,~~ and the expense is recorded over the applicable requisite service period using the accelerated attribution method. Forfeitures are recognized as and when they occur. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price based on peer companies, the expected dividends on the underlying shares and the risk-free interest rate.

The terms of the Company’s equity-based compensation plans permit an employee holding vested stock options to elect to have the Company withhold a portion of the shares ~~that are issued~~otherwise issuable upon anthe employee's exercise of anthe option, ~~to be withheld through~~ a ~~net~~so-called "net settlement transaction," as a means of paying the exercise price meeting tax withholding ~~requirements.~~requirements, or both.

Marketable Securities

Marketable securities consist of investments that have a readily determinable fair value based on quoted market price of the investment, which is considered a Level 1 fair value measurement. Under ASC 320, Investments—Debt and Equity Securities, these investments are classified as available-for-sale and are reported at fair value in other current assets on the Company's consolidated balance sheet. Unrealized holding gains and losses are reported within accumulated other comprehensive ~~income.~~income/(loss). Under the Company's accounting policy, a decline in the fair value of marketable securities is deemed to be "other than temporary" and such marketable securities are generally considered to be impaired if their fair value is less than the Company's cost basis for a period based on the particular facts and circumstances surrounding the investment. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge.

1213

Table of Contents

Recent Financial Accounting Standards

Recently Adopted Accounting Standards

In ~~October 2016,~~July 2015, the Financial Accounting Standards Board ~~("FASB"~~(the "FASB") issued Accounting Standards Update ~~(“ASU”~~("ASU") ~~2016-16, Accounting for Income Taxes: Intra-Entity Asset Transfers~~2015-11, Simplifying the Measurement of ~~Assets Other than~~ Inventory, which ~~reduces~~requires an entity to measure inventory at lower of cost and net realizable value. Net realizable value is the ~~complexity~~estimated selling prices in ~~accounting~~the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The ASU is effective for ~~income taxes by requiring~~public reporting entities in fiscal years beginning after December 15, 2016. The Company adopted this ASU prospectively in fiscal 2018. The adoption of this ASU did not have any material impact to the ~~recognition~~Company's consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15 Statement of ~~current~~Cash Flows (Topic 230): Classification of Certain Cash Receipts and ~~deferred income taxes for an intra-entity asset transfer, other than inventory, when~~Cash Payments, which provides clarification on the ~~transfer occurs. Historically,~~presentation and classification of certain cash receipts and cash payments in the ~~income tax consequence~~statement of ~~these transactions was not recognized until the asset was sold to an outside party.~~cash flows. The guidance ~~will be applied on a modified retrospective basis with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The ASU~~ will be effective for publicly reporting entities in fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted only in the first interim period of a fiscal year. The Company elected to adopt ASU 2016-16 effective July 1, 2016, which resulted in a cumulative-effect adjustment of $34.2 million charged to the opening balance of the accumulated deficit, reduction to other non-current and current assets of $45.6 million and $6.6 million, respectively, increase in deferred tax assets of $14.7 million, and reduction of deferred tax liabilities of $3.2 million. The impact on net earnings and earnings per share in the current period was not material.

~~In March 2016, the FASB issued~~ ~~ASU 2016-09 Improvements to Employee Share-Based Payment Accounting~~, which simplifies the accounting for share-based payment transactions, requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings. An entity can make an accounting policy election to either estimate the expected future forfeiture of awards or account for the cost or benefit as forfeitures occur. The guidance will be effective for publicly reporting entities in fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period. The Company ~~early-adopted~~early adopted this ASU ~~2016-09 during the fourth quarter of~~retrospectively in fiscal ~~2016 on a modified retrospective basis, which had an effect on the consolidated statements of operations, comprehensive income/(loss), and cash flows for the nine months ended March 31, 2016.~~2018. The consolidated statements of comprehensive income/(loss) and cash flows for the nine months ended March 31, 2016 have been adjusted to reflect the changes in net earnings during that period as a result of the adoption of ~~the new guidance. The following table summarizes the Company's As Reported and As Adjusted changes to the consolidated statement of operations for the nine months ended March 31, 2016 (in millions):~~

Three Months Ended Nine Months Ended
March 31, 2016 March 31, 2016
(Dollars in millions, except per share amounts) As Reported As Adjusted As Reported As Adjusted
Selling, general and administrative expenses $ 93.2
$ 93.4
$ 268.4
$ 268.6
Earnings from continuing operations before income taxes 14.0
13.8
67.6
67.4
Income tax expense/(benefit) 4.2
3.1
$ 18.3
$ 14.3
Net earnings 9.8
10.7
49.3
53.1
Net earnings attributable to Catalent $ 9.8
$ 10.7
$ 49.6
$ 53.4

Earnings per share attributable to Catalent:
Basic
Net earnings 0.08
0.09
0.40
0.43
Diluted
Net earnings 0.08
0.09
0.39
0.42

~~In May 2015, the FASB issued~~ this ASU ~~No. 2015-07Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent),~~ which removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. This guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, such disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. This guidance is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company has adopted ASU 2015-07 effective July 1, 2016, the beginning of its fiscal year ending June 30, 2017, in accordance with the FASB's disclosure simplification initiatives. The adoption did not have aany material impact onto the Company's consolidated financial statements.

~~Table of Contents~~

New Accounting Standards Not Adopted as of ~~March~~December 31, 2017

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which reduces the complexity of and simplifies the application of hedge accounting by preparers. The ASU will be effective for fiscal years beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when an entity will apply modification accounting for changes to stock-based compensation arrangements. Modification accounting applies if the value, vesting conditions, or classification of the awards changes. The ASU will be effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which requires entities to report the service cost component of the net periodic benefit cost in the same income statement line as other compensation costs arising from services rendered by employees during the reporting period. The other components of the net benefit costs will be presented in the income statement separately from the service cost and below the income from operations subtotal. The ASU will be effective for public reporting entities in fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted in the first interim period of a fiscal year. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

In January 2017, the FASB issued ASU ~~2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment~~, which eliminates Step 2 of the current goodwill impairment test, the requirement to calculate the implied fair value of goodwill in measuring the goodwill impairment charge. Instead, under this update, the impairment charge will be measured based on the excess of a reporting unit's carrying value over its fair value. The ASU will be effective for public reporting entities in fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. The Company will early adopt this guidance during the fourth quarter of fiscal 2017 when the annual goodwill impairment test is completed and apply the guidance prospectively. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

~~In January 2017, the FASB issued~~ ~~ASU~~ 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which provides additional guidance on the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The ASU will be effective for public reporting entities in fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. ~~The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.~~

~~In August 2016, the FASB issued~~ ~~ASU 2016-15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments~~, which provides clarification on the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The guidance will be effective for publicly reporting entities in fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02 Leases (Topic 842), which will supersede ASC 840 Leases. The new guidance requires lessees to recognize most leases on their balance sheets for the rights and obligations created by those leases. The guidance requires enhanced disclosures regarding the amount, timing and uncertainty of cash flows arising from leases and will be effective for publicly reporting entities in annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance is required to be adopted using the modified retrospective approach. The Company ~~is currently evaluating~~anticipates that most of its operating leases will result in the recognition of additional assets and corresponding liabilities on its consolidated balance sheets. The Company continues to evaluate the impact of adopting this guidance and its implication on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers, which will supersede nearly all existing revenue recognition guidance. The new guidance’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, the new guidance creates a five-step model that requires a

Table of Contents

company to exercise judgment when considering the terms of the contracts and all relevant facts and circumstances. The five steps require a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations and recognize revenue when each performance obligation is satisfied. On July 9, 2015, the FASB approved a one-year deferral of the effective date so that the new guidance is effective for public entities for annual and interim periods beginning after December 15, 2017. The new guidance allows for either full retrospective adoption, where the standard is applied to all periods presented, or modified retrospective adoption where the standard is applied only to the most current period presented in the financial statements. Early adoption is permitted. The Company has identified its revenue streams, reviewed the initial impacts of adopting of the new standard on those revenue streams, and appointed a governance committee and project management leader. ~~The~~While the Company continues to ~~evaluate the quantitative and qualitative~~assess all potential impacts of the ~~standard.~~ standard, it has preliminarily assessed that the timing of revenue recognition may change for certain contractual arrangements containing minimum volume commitments in which the price is not fixed or determinable pursuant to the terms of the agreement. Under the current standard, the related pricing adjustments are considered to be contingent, while under the new standard they will likely be accounted for as variable consideration and revenue might be recognized earlier provided that the Company can reliably estimate the amount expected to be realized. Further, the Company has preliminarily determined that, for commercial supply arrangements, revenue will be recognized at the point in time of completing the required quality assurance process. The Company expects to adopt the new standard on a modified retrospective basis.


2.	BUSINESS COMBINATIONS

Transaction Overview:

On October 23, 2017, the Company acquired 100% of the equity interest in Cook Pharmica LLC (now doing business as Catalent Indiana, LLC, "Catalent Indiana") for an aggregate nominal purchase price of $950 million, subject to adjustment, in order to enhance the Company's biologics capabilities. Catalent Indiana is a biologics-focused contract development and manufacturing organization with capabilities across biologics development, clinical and commercial cell culture manufacturing, formulation, finished-dose manufacturing, and packaging.

The Company accounted for the transaction using the acquisition method of accounting for business combinations, in accordance with ASC 805 Business Combinations. The total consideration was (in thousands):



Cash paid at closing	$	748,002
Fair value of deferred consideration at closing		184,838
Total consideration	$	932,840

In ~~August 2014,~~addition to the ~~FASB issued~~ ~~ASU No. 2014-15Disclosure~~cash paid at the closing of ~~Uncertainties about~~the acquisition, the agreement governing the purchase includes a deferred consideration arrangement that requires the Company to pay an ~~Entity's Ability to Continue~~additional $200.0 million in $50.0 million increments on each of the first four anniversaries of the closing. The fair value of the deferred consideration recognized on the acquisition date was estimated by calculating the risk-adjusted present value of four deferred cash payments and includes a component of imputed interest. This deferred consideration is included in current and long-term obligations within the consolidated balance sheet at December 31, 2017.

Following the acquisition, the operating results of the Catalent Indiana business have been included in the consolidated financial statements. For the period from the acquisition date through December 31, 2017, Catalent Indiana's net revenue was $40.4 million and pre-tax earnings were $7.9 million. Transaction costs incurred as a ~~Going Concern,~~ result of the acquisition of $1.9 million and $10.4 million are included in selling, general and administrative expenses for the three and six months ending December 31, 2017, respectively.

Valuation Assumptions and Preliminary Purchase Price Allocation:

The Company estimated fair values at the date of acquisition for the preliminary allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed. During the measurement period, the Company will continue to obtain information to assist in finalizing the fair value of net assets acquired, which ~~requires management to evaluate, for each annual and interim~~may differ materially from these preliminary estimates. If any measurement period adjustment is material, the Company will record those adjustments, including any related impact on net income, in the reporting period ~~whether there~~in which the adjustments are ~~conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going~~determined.

1415

Table of Contents

~~concern within one year after~~The preliminary purchase price allocation to assets acquired and liabilities assumed in the transaction is (in thousands):



Accounts Receivable	$	37,021
Inventory		25,144
Other current assets		1,344
Property, plant and equipment		221,139
Identifiable intangible assets		330,000
Trade and other payables		5,380
Deferred revenue		18,132
Total identifiable net assets		591,136
Goodwill		341,704
Total assets acquired and liabilities assumed	$	932,840

The carrying value of trade receivables, raw materials inventory and trade payables, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition.

Property, plant and equipment was valued using a combination of the ~~financial statements are issued or are available to be issued. If substantial doubt~~sales comparison approach and cost approach, which is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. This standard is not expected to have any impactbased on current ~~disclosures~~replacement and/or reproduction cost of the asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets.

Customer relationship intangible assets of $330 million were valued using the multi-period excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, selling and marketing costs, return on working capital, contributory asset charges and other factors), the discount rate which appropriately reflects the risk inherent in each future cash flow stream, the assessment of the asset’s life cycle, as well as other factors. The assumptions used in the financial ~~statements.~~ forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market comparable information. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. Preliminary assumptions may change and may result in significant changes to the final valuation. The customer relationship intangible asset has a weighted average useful life of 14 years.

Goodwill has preliminarily been allocated to our Drug Delivery Solutions segment as shown in Note 3, Goodwill. Goodwill is expected to be deductible for tax purposes and is mainly comprised of the following: growth from an expected increase in capacity utilization, potential new customers and the biologic expertise and know-how acquired with the acquisition of Catalent Indiana's workforce.

Pro Forma Results:

The following table provides unaudited pro forma results for the Company, prepared in accordance with ASC 805, for the three and six months ended December 31, 2017 and December 31, 2016, as if the Company had acquired Catalent Indiana as of July 1, 2016.



	For the Three Months Ended					For the Six Months Ended
	December 31, 2017			December 31, 2016		December 31, 2017			December 31, 2016
	(in millions, except per share data)
Revenue	$	621.0		$	531.1	$	1,216.2		$	1,016.6
Net income/(loss)	(10.5		)	17.6		(1.0		)	(0.6		)
Basic earnings/(loss) per share	(0.08		)	0.13		(0.01		)	0.00
Diluted earnings/(loss) per share	(0.08		)	0.13		(0.01		)	0.00

The unaudited pro forma financial information was prepared based on the historical information of Catalent and Catalent Indiana. In order to reflect the acquisition on July 1, 2016, the unaudited pro formal financial information includes adjustments

Table of Contents

to reflect the incremental amortization expense to be incurred based on the fair value of the intangible assets acquired, the incremental depreciation expense related to the fair value adjustments associated with Catalent Indiana's property, plant and equipment, the additional interest expense associated with the issuance of debt to finance the acquisition, the shares issued in connection with the first quarter equity offering to finance the acquisition, and the acquisition, integration, and financing-related costs incurred during the three and six months ended December 31, 2017 and 2016. The results do not include any anticipated cost savings or other effects associated with integrating Catalent Indiana into the rest of the Company. Unaudited pro forma amounts are not necessarily indicative of results had the acquisition occurred on July 1, 2016 or of future results.


2.3.	GOODWILL

The following table summarizes the changes between June 30, ~~2016~~2017 and ~~March~~December 31, 2017 in the carrying amount of goodwill in total and by reporting segment:


(Dollars in millions)	Softgel Technologies			Drug Delivery Solutions			Clinical Supply Services			Total			Softgel Technologies			Drug Delivery Solutions		Clinical Supply Services		Total
Balance at June 30, 2016	$	405.9		$	435.1		$	155.5		$	996.5
Balance at June 30, 2017													$	415.2		$	477.2	$	151.7	$	1,044.1
Additions	4.5			48.5			—			53.0			—			341.7		—		341.7
Divestitures													(0.9		)	—		—		(0.9		)
Foreign currency translation adjustments	(1.6		)	(10.3		)	(7.0		)	(18.9		)	8.9			8.3		6.2		23.4
Balance at March 31, 2017	$	408.8		$	473.3		$	148.5		$	1,030.6
Balance at December 31, 2017													$	423.2		$	827.2	$	157.9	$	1,408.3

The ~~$48.5 million addition~~reduction in goodwill ~~within DDS is associated with the acquisition of Pharmatek Laboratories, Inc. ("Pharmatek") in September 2016 and the preliminary fair value allocation. The Company is~~ in the ~~process~~Softgel Technologies reporting segment relates to the sale of ~~finalizing~~two manufacturing sites in the ~~valuation of~~Asia Pacific region. The site divestitures were neither material individually or in aggregate to the ~~individual assets acquired and liabilities assumed.~~segment or to the Company. The goodwill addition reported above is based on management's best current estimate. The fair value allocation is expected to be completed upon finalization of an independent appraisal over the next several months, but no later than one year from the acquisition date.

~~The $4.5 million addition~~increase in goodwill ~~within Softgel Technologies is associated with the acquisition of Accucaps Industries Limited ("Accucaps") in February 2017 and the preliminary fair value allocation. The Company is~~ in the ~~process of finalizing~~Drug Delivery Solutions reporting segment relates to the valuation of the individual assets acquired and liabilities assumed. The goodwill addition reported above is based on management's best current estimate. The fair value allocation is expected to be completed upon finalization of an independent appraisal over the next several months, butCatalent Indiana acquisition. See note 2 Business Combinations. There were no ~~later than one year from the acquisition date.~~

~~No goodwill~~ impairment ~~charge was required during~~charges recorded in the current ~~or comparable prior year~~ period. ~~When required, impairment charges are recorded within the consolidated statements of operations as impairment charges and (gain)/loss on sale of assets.~~


3.4.	DEFINITE LIVED LONG-LIVED ASSETS

The Company’s definite-lived long-lived assets include property, plant and equipment as well as other intangible assets with definite lives. Refer to Note 1415 Supplemental Balance Sheet Information for details related to property, plant, and equipment.

The details of other intangible assets subject to amortization as of ~~March~~December 31, 2017 and June 30, ~~2016~~2017, are as follows:


(Dollars in millions)	Weighted Average Life	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Weighted Average Life	Gross Carrying Value		Accumulated Amortization			Net Carrying Value
March 31, 2017
December 31, 2017
Amortized intangibles:
Core technology	18 years	$	168.3	$	(71.3	)	$	97.0	18 years	$	172.7	$	(81.2	)	$	91.5
Customer relationships	14 years	251.4		(100.5		)	150.9		14 years	589.3		(121.2		)	468.1
Product relationships	12 years	203.7		(169.0		)	34.7		12 years	212.0		(189.6		)	22.4
Total intangible assets		$	623.4	$	(340.8	)	$	282.6		$	974.0	$	(392.0	)	$	582.0

The increase in customer relationships is associated with the ~~preliminary fair value allocation~~acquisition of Catalent Indiana in October 2017. Refer to Note 2 Business Combinations for details of the ~~acquisitions of Pharmatek in September 2016 and Accucaps in February 2017.~~acquisition.



(Dollars in millions)	Weighted Average Life	Gross Carrying Value		Accumulated Amortization			Net Carrying Value
June 30, 2017
Amortized intangibles:
Core technology	18 years	$	170.3	$	(74.8	)	$	95.5
Customer relationships	14 years	253.0		(106.1		)	146.9
Product relationships	12 years	206.9		(176.2		)	30.7
Total intangible assets		$	630.2	$	(357.1	)	$	273.1

1517

Table of Contents

(Dollars in millions) Weighted Average Life
Gross
Carrying
Value

Accumulated
Amortization

Net
Carrying
Value
June 30, 2016
Amortized intangibles:
Core technology 18 years $ 170.6
$ (64.9 ) $ 105.7
Customer relationships 14 years 230.3
(90.9 ) 139.4
Product relationships 12 years 208.6
(159.7 ) 48.9
Total intangible assets $ 609.5
$ (315.5 ) $ 294.0

Amortization expense was ~~$11.0~~$16.1 million and ~~$33.1~~27.5 million for the three and ~~nine~~six months ended ~~March~~December 31, 2017, respectively, and ~~$11.4~~$11.1 million and ~~$35.0~~$22.1 million for the three and ~~nine~~six months ended ~~March~~December 31, 2016, respectively. Future amortization expense for the next five fiscal years is estimated to be:


(Dollars in millions)	Remainder Fiscal 2017		2018		2019		2020		2021		2022		Remainder Fiscal 2018		2019		2020		2021		2022		2023
Amortization expense	$	11.1	$	44.3	$	38.8	$	25.3	$	25.3	$	25.3	$	34.8	$	63.8	$	49.7	$	49.7	$	49.7	$	49.7


4.5.	LONG-TERM OBLIGATIONS AND OTHER SHORT-TERM BORROWINGS

Long-term obligations and other short-term borrowings consist of the following at ~~March~~December 31, 2017 and June 30, ~~2016~~2017:


(Dollars in millions)	Maturity	March 31, 2017		June 30, 2016		Maturity as of December 31, 2017	December 31, 2017		June 30, 2017
Senior Secured Credit Facilities
Term loan facility dollar-denominated	May 2021	$	1,247.2	$	1,454.2	May 2024	$	1,234.9	$	1,244.2
Term loan facility euro-denominated	May 2021	337.8		345.2		May 2024	366.5		352.0
4.75% Senior Euro-denominated Notes	December 2024	406.2		—
$200 million Revolving Credit Facility	May 2019	—		—
Euro-denominated 4.75% Senior Notes due 2024						December 2024	445.4		424.3
U.S. dollar-denominated 4.875% Senior Notes due 2026						January 2026	443.7		—
Deferred purchase consideration						September 2021	186.0		—
$200 million revolving credit facility						May 2022	—		—
Capital lease obligations	2020 to 2032	52.7		51.4		2020 to 2032	62.8		53.3
Other obligations	2017 to 2018	5.1		9.7		2018 to 2019	3.1		5.9
Total		2,049.0		1,860.5			2,742.4		2,079.7
Less: Current portion of long-term obligations and other short-term borrowings		23.7		27.7			69.9		24.6
Long-term obligations, less current portion		$	2,025.3	$	1,832.8		$	2,672.5	$	2,055.1

Senior Secured Credit Facilities and ~~Second~~Third Amendment

Borrowings under Operating Company's term loan facilities and the revolving credit facility originally bore interest, at Operating Company’s option, at a rate equal to a margin over either (a) a base rate determined by reference to the higher of (1) the rate of interest published by The Wall Street Journal as its “prime lending rate” and (2) the federal funds rate plus one-half of 1% or (b) a LIBOR rate determined by reference to the London Interbank Offered Rate set by ICE Benchmark Administration (or any successor thereto). The applicable margin for the term loans and borrowings under the revolving credit facility may be reduced subject to Operating Company attaining a certain total net leverage ratio. The applicable margin for borrowings was originally 3.25% for loans based on a LIBOR rate and 2.50% for loans based on a base rate. The LIBOR rate for term loans is subject to a floor of 1.00% and the base rate for term loans is subject to a floor of 2.00%.

~~Table of Contents~~

On ~~December 9, 2016,~~October 18, 2017, Operating Company completed ~~the Second~~ Amendment No. 3 (the ~~"Amendment"~~"Third Amendment") to ~~the~~its Amended and Restated Credit Agreement, dated as of May 20, 2014 ~~governing all term loan and revolving credit facilities~~ (as subsequently amended, the "Credit Agreement") ~~to lower~~, governing the senior secured credit facilities that provide U.S. dollar denominated term loans, euro-denominated term loans and a revolving credit facility. The Third Amendment lowered the interest rate on ~~its~~ U.S. dollar-denominated and euro-denominated term ~~loans.~~loans and the revolving credit facility and extended the maturity dates on the senior secured credit facilities by three years. The new applicable rate for ~~the~~ U.S. dollar-denominated term ~~loan~~loans is LIBOR ~~(subject~~(the London Interbank Offered Rate, subject to a floor of 1.00%) plus ~~2.75%~~2.25%, which is 0.50% lower than the previous rate, and the new applicable rate for ~~the~~ euro-denominated term loans is LIBOR (subject to a floor of 1.00%) plus ~~2.50%~~1.75%, which is 0.75% lower than the previous rate. The ~~Amendment further eliminates “step” pricing~~new applicable rate for the revolving loans is initially LIBOR plus 2.25%, which is 1.25% lower than the previous rate, and such rate can additionally be reduced to LIBOR plus 2.00% in future periods based on a measure of Operating Company's total leverage ratio. The term loans and revolving loans will now mature in May 2024 and May 2022, respectively. The Third Amendment also includes a prepayment ~~premium~~ of 1.0% in the event of another repricing event on or before the six-month anniversary of the Third Amendment. There is no change to maturities or covenants as a result of the Amendment. In connection with the Amendment, the Company incurred $1.7 million of associated fees, which were expensed in Other (Income) / Expense, net in the consolidated statement of operations.

Euro-denominated 4.75% Senior ~~Euro-denominated~~ Notes due 2024

On December 9, 2016, Operating Company, completed a private offering of €380.0 million aggregate principal amount of 4.75% Senior Notes due 2024 (the ~~“Notes”~~"Euro Notes"). The Euro Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The Euro Notes were offered in the United States to qualified institutional buyers in reliance on Rule 144A under the Securities Act ~~of 1933, as amended (the “Securities Act”)~~ and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. The Euro Notes will mature on December 15, 2024, ~~and~~ bear interest at the rate of 4.75% per annum and are payable semi-annually in arrears on June 15 and December 15 of each year.

Table of Contents

U.S. Dollar-denominated 4.875% Senior Notes due 2026

On October 18, 2017, Operating Company completed a private offering (the "Debt Offering") of $450.0 million aggregate principal amount of 4.875% senior unsecured notes due 2026 (the "USD Notes"). The USD Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The USD Notes were offered in the United States to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. The USD Notes will mature on January 15, 2026, bear interest at the rate of 4.875% per annum, and are payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The net proceeds of the ~~Notes~~Debt Offering, after payment of the initial purchasers' discount and related fees and expenses, were used to repay $200 million of outstanding borrowings on the U.S. dollar-denominated term loan, pay the $81 million then outstanding under the revolving credit facility, pay accrued and unpaid interest and certain fees and expenses associated with the offering, fund a ~~previously announced pending~~portion of the consideration for the Catalent Indiana acquisition ~~and provide cash for general corporate purposes.~~ due at its closing.

Deferred Purchase Consideration

In connection with the ~~Notes offering and subsequent payment~~acquisition of Catalent Indiana in October 2017, $200 million of the ~~U.S. dollar-denominated term~~$950 million aggregate nominal purchase price is payable in $50 million installments, on each of the first four anniversaries of the closing date. The deferred purchase consideration is recorded at fair value and includes a component of imputed interest.

Bridge Loan Facility

On September 18, 2017, contemporaneous with the Company entering into the agreement to acquire Catalent Indiana, Operating Company entered into a debt commitment letter with Morgan Stanley Senior Funding, Inc., JP Morgan Chase Bank, N.A., Royal Bank of Canada, RBC Capital Markets, Bank of America, N.A. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as commitment parties. Pursuant to the debt commitment letter and subject to its terms and conditions, the commitment parties agreed to provide a senior unsecured bridge loan facility (the "Bridge Facility") of up to $700.0 million in the aggregate for the purpose of providing any back-up financing necessary to fund a portion of the consideration to be paid in the acquisition and related fees, costs and expenses (the "Bridge Loan Commitment"). In connection with entering into the Bridge Facility, Operating Company incurred ~~$6.9~~$6.1 million of ~~third-party financing costs, of~~associated fees, which ~~$0.6 million~~ was ~~expensed, and a $2.0 million expense related to unamortized debt discount and deferred financing costs, both~~ recorded in ~~Other (Income) / Expense, net~~prepaid expenses and other in the consolidated ~~statement~~balance sheet as of ~~operations.~~September 30, 2017. Operating Company did not draw on it to fund the acquisition and the Company expensed the $6.1 million in the second quarter as part of other income and expense and the facility was closed. See Note 7 for further discussion of financing costs incurred in the second quarter.

Debt Covenants

Senior Secured Credit Facilities

The Credit Agreement contains a number of covenants that, among other things, restrict, subject to certain exceptions, Operating Company’s (and Operating Company’s restricted subsidiaries’) ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; enter into sale and leaseback ~~transactions,~~transactions; amend material agreements governing Operating Company’s subordinated ~~indebtedness~~indebtedness; and change Operating Company’s lines of business.

The Credit Agreement also contains change of control provisions and certain customary affirmative covenants and events of default. The revolving credit facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of ~~March~~December 31, 2017, ~~the~~Operating Company was in compliance with all material covenants related to its ~~senior-secured~~long-term obligations.

Subject to certain exceptions, the Credit Agreement permits Operating Company and its restricted subsidiaries to incur certain additional indebtedness, including secured indebtedness. None of Operating Company’s non-U.S. subsidiaries or Puerto Rico subsidiaries is a guarantor of the loans.

Under the Credit Agreement, Operating Company’s ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as “Consolidated EBITDA” in the Credit Agreement). Adjusted EBITDA is based on the definitions in the Credit Agreement, is not defined under U.S. GAAP, and is subject to important limitations.

~~4.75% Senior Euro-denominated~~The Euro Notes and the USD Notes

The ~~Indenture~~Indentures governing the Euro Notes ~~contains~~and the USD Notes (the "Indentures") contain certain covenants that, among other things, limit the ability of Operating Company and its restricted subsidiaries to incur or guarantee more debt or issue certain preferred shares, pay dividends on, repurchase or make distributions in respect of their capital stock or make other

Table of Contents

restricted payments, make certain investments, sell certain assets, create liens, consolidate, merge, sell or otherwise dispose of all or substantially all of their assets, enter into certain transactions with their affiliates, and designate their subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions, limitations and qualifications as set forth in the ~~Indenture.~~Indentures. The ~~Indenture~~Indentures also ~~contains~~contain customary events of default including, but not limited to, nonpayment, breach of covenants, and payment or acceleration

~~Table of Contents~~

defaults in certain other indebtedness of Operating Company or certain of its subsidiaries. Upon an event of default, either the holders of at least 30% in principal amount of each of the then-outstanding Euro Notes or the ~~Trustee~~then-outstanding USD Notes, or either of the Trustees under the Indentures, may declare the ~~Notes~~applicable notes immediately due and payable, or in certain circumstances, the ~~Notes automatically~~applicable notes will become automatically immediately due and payable. As of ~~March~~December 31, 2017, ~~the~~Operating Company was in compliance with all material covenants ~~related to~~under the ~~Notes.~~Indentures.

Fair Value of Debt Instruments

The estimated fair value of the senior secured credit facility, a Level 2 fair value estimate, is based on the quoted market prices for the same or similar issues or on the current rates offered for debt of the same remaining maturities and considers collateral, if any. The estimated fair value of the Euro and USD Notes, a Level 1 fair value estimate, is based on the quoted market prices of the ~~instrument.~~instruments. The carrying amounts and the estimated fair values of financial instruments as of ~~March~~December 31, 2017 and June 30, ~~2016~~2017 are as follows:


		March 31, 2017				June 30, 2016					December 31, 2017				June 30, 2017
(Dollars in millions)	Fair Value Measurement	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value		Fair Value Measurement	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
4.75% Senior Euro-denominated Notes	Level 1	$	406.2	$	429.6	$	—	$	—
Euro-denominated 4.75% Senior Notes										Level 1	$	445.4	$	474.4	$	424.3	$	454.0
U.S. Dollar-denominated 4.875% Senior Notes										Level 1	443.7		449.8		—		—
Senior Secured Credit Facilities & Other	Level 2	1,642.8		1,649.2		1,860.5		1,868.8		Level 2	1,853.3		1,825.1		1,655.4		1,653.1
Total		$	2,049.0	$	2,078.8	$	1,860.5	$	1,868.8		$	2,742.4	$	2,749.3	$	2,079.7	$	2,107.1


5.6.	EARNINGS PER SHARE

The reconciliations between basic and diluted earnings per share attributable to Catalent common shareholders for the three and ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively, are as follows ~~(dollars in~~(in millions, except share and per share data):


	Three Months Ended March 31,				Nine Months Ended March 31,				Three Months Ended December 31,					Six Months Ended December 31,
	2017		2016		2017		2016		2017			2016		2017			2016
Net earnings attributable to Catalent	$	26.0	$	10.7	$	48.0	$	53.4
Net earnings/(loss)									$	(21.9	)	$	17.4	$	(18.1	)	$	22.0

Weighted average shares outstanding	124,951,928		124,809,898		124,897,130		124,793,732		132,983,262			124,889,681		129,327,188			124,870,327
Dilutive securities issuable-stock plans	1,847,202		962,861		1,587,196		1,139,309		—			1,524,963		—			1,470,476
Total weighted average diluted shares outstanding	126,799,130		125,772,759		126,484,326		125,933,041		132,983,262			126,414,644		129,327,188			126,340,803

Basic earnings per share of common stock:
Net earnings attributable to Catalent	$	0.21	$	0.09	$	0.38	$	0.43
Net earnings/(loss)									$	(0.16	)	$	0.14	$	(0.14	)	$	0.18

Diluted earnings per share of common stock - assuming dilution:
Net earnings attributable to Catalent	$	0.21	$	0.09	$	0.38	$	0.42
Diluted earnings per share of common stock:
Net earnings/(loss)									$	(0.16	)	$	0.14	$	(0.14	)	$	0.17

The computation of diluted earnings per share for the three and ~~nine~~six months ended ~~March~~December 31, 2017 excludes the maximum effect of the potential common shares issuable under the employee stock option plan of approximately 2.6 million shares, and excludes restricted share awards of 2.1 million shares, because the Company had a net loss for the period and the effect would therefore be anti-dilutive. The computation of diluted earnings per share for the three and six months ended December 31, 2016 excludes the effect of 0.5 million shares potentially issuable pursuant to awards granted under the 2007 Stock Incentive Plan, because the vesting provisions of those awards specify ~~performance-based~~performance- or market-based conditions that had not been met as of the period end. The computation of diluted earnings per share for the three and ~~nine~~six months ended ~~March~~December 31, 2016 excludes the effect of 2.0 million shares potentially issuable pursuant to awards granted under the 2007 Stock Incentive Plan and the 2014 Omnibus Incentive Plan, because the vesting provisions of those awards specify performance- or market-based conditions that had not been met as of the period end. Further, the computation of diluted earnings per share for the three months ended March 31, 2017 and 2016 excludes the effect of potential common shares issuable under the employee-held stock options and restricted stock units of approximately 0.8 million and 1.0 million shares, respectively, because they are anti-dilutive. The computation of diluted earnings per share for the nine months ended March 31, 2017 and 2016 excludes the effect of potential common shares issuable under the employee-held stock options and restricted stock units of approximately 0.9 million and ~~1.2~~1.1 million shares, respectively, because they are anti-dilutive.

1820

Table of Contents


6.7.	OTHER (INCOME)/EXPENSE, NET

The components of ~~Other (Income)~~ other (income)/ ~~Expense,~~expense, net for the three and ~~nine~~six months ended ~~March~~December 31, 2017 and 2016 are as follows:


	Three Months Ended March 31,					Nine Months Ended March 31,						Three Months Ended December 31,					Six Months Ended December 31,
(Dollars in millions)	2017		2016			2017			2016			2017		2016			2017		2016
Other (income) / expense, net
Other (income)/expense, net
Debt refinancing costs ⁽¹⁾	$	—	$	—		$	4.3		$	—		$	11.8	$	4.3		$	11.8	$	4.3
Foreign currency (gains) and losses	7.3		(3.6		)	(0.2		)	(7.5		)	1.3		(5.3		)	6.9		(7.5		)
Other	—		(0.6		)	(0.7		)	0.4			0.5		(0.8		)	0.6		(0.7		)
Total Other (Income) / Expense, net	$	7.3	$	(4.2	)	$	3.4		$	(7.1	)
Total other (income)/expense, net												$	13.6	$	(1.8	)	$	19.3	$	(3.9	)

(1) ~~Refer~~The 2017 debt refinancing costs include financing charges related to ~~Note 4~~the offering of the USD Notes and the Third Amendment and also include a $6.1 million charge for ~~discussions~~commitment fees paid during the first quarter of fiscal 2018 on the Bridge Facility. The 2016 debt refinancing costs include financing charges of $4.3 million related to the December 2016 ~~re-financing activity.~~offering of the Euro Notes and repricing and partial paydown of the Company's term loans.


7.8.	RESTRUCTURING AND OTHER COSTS

Restructuring Costs

The Company has implemented plans to restructure certain operations, both domestically and internationally. The restructuring plans focused on various aspects of operations, including closing and consolidating certain manufacturing operations, rationalizing headcount and aligning operations in a strategic and more cost-efficient structure. In addition, the Company may incur restructuring charges in the future in cases where a material change in the scope of operation with its business occurs. Employee-related costs consist primarily of severance costs and also include outplacement services provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. Facility exit and other costs consist of accelerated depreciation, equipment relocation costs and costs associated with planned facility expansions and closures to streamline Company operations.

Other Costs / (Income)

Other ~~costs include~~income includes settlement charges, net of any insurance recoveries related to the probable resolution of certain customer claims related to ~~the~~a previous temporary suspension of operations at ~~our~~a softgel manufacturing ~~facility in Beinheim, France.~~facility. Refer to Note 1213 Commitments and Contingencies for further discussions of such claims.

The following table summarizes the significant costs recorded within restructuring costs:


	Three Months Ended March 31,					Nine Months Ended March 31,					Three Months Ended December 31,						Six Months Ended December 31,
(Dollars in millions)	2017			2016		2017			2016		2017			2016			2017			2016
Restructuring costs:
Employee-related reorganization	$	3.1		$	1.8	$	3.7		$	3.4	$	1.6		$	(0.1	)	$	3.3		$	0.7
Facility exit and other costs	(3.0		)	—		(2.4		)	—		(0.7		)	0.2			(0.2		)	0.5
Total restructuring costs	$	0.1		$	1.8	$	1.3		$	3.4	$	0.9		$	0.1		$	3.1		$	1.2
Other - Beinheim customer claims	—			—		3.2			—
Other - customer claims net of insurance recoveries											(0.8		)	3.2			(1.8		)	3.2
Total restructuring and other costs	$	0.1		$	1.8	$	4.5		$	3.4	$	0.1		$	3.3		$	1.3		$	4.4


8.9.	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company is exposed to fluctuations in the applicable exchange rate on its investments in foreign operations. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated its exposure from its investments in its European operations by denominating a portion of its debt in euros. At ~~March~~December 31, 2017, the Company had euro-denominated debt outstanding of $~~744.0~~811.9 million that is designated and qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portions of the translation gains or losses are reported in accumulated other comprehensive income/(loss) as part of the cumulative translation adjustment. The ineffective portions of the translation gains or losses are reported in the statement of operations. The following table includes net investment hedge activity during the three and ~~nine~~six months ended ~~March~~December 31, 2017 and ~~March~~December 31, 2016.

1921

Table of Contents


	Three Months Ended March 31,						Nine Months Ended March 31,						Three Months Ended December 31,					Six Months Ended December 31,
(Dollars in millions)	2017			2016			2017			2016			2017			2016		2017			2016
Unrealized foreign exchange gain/(loss) within other comprehensive income	$	(13.9	)	$	(4.1	)	$	(3.9	)	$	(1.6	)	$	(3.9	)	$	13.6	$	(21.5	)	$	10.0
Unrealized foreign exchange gain/(loss) within statement of operations	$	(13.5	)	$	(3.1	)	$	(5.9	)	$	1.3		$	(2.8	)	$	10.2	$	(16.2	)	$	7.6

The net accumulated gain of the instrument designated as the hedge as of ~~March~~December 31, 2017 within other comprehensive income/(loss) was approximately ~~$77.5~~$38.5 million. Amounts are reclassified out of accumulated other comprehensive income/(loss) into earnings when the entity to which the gains and losses relate is either sold or substantially liquidated.


9.10.	INCOME TAXES

U.S. Tax Reform

On December 22, 2017, the U.S. government enacted wide-ranging tax legislation, the Tax Cuts and Jobs Act (the "2017 Tax Act"). The 2017 Tax Act significantly revises U.S. tax law by, among other provisions, (a) lowering the applicable U.S. federal statutory income tax rate from 35% to 21%, (b) creating a partial territorial tax system that includes imposing a mandatory one-time transition tax on previously deferred foreign earnings, (c) creating provisions regarding the (1) Global Intangible Low Tax Income ("GILTI"), (2) the Foreign Derived Intangible Income ("FDII") deduction, and (3) the Base Erosion Anti-Abuse Tax ("BEAT"), and (d) eliminating or reducing certain income tax deductions, such as interest expense, executive compensation expenses and certain employee expenses.

ASC 740 Income Taxes requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the 2017 Tax Act’s provisions, the SEC staff issued Staff Accounting Bulletin No. 118 ("SAB 118"), which allows companies to record the tax effects of the 2017 Tax Act on a provisional basis based on a reasonable estimate and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment. As a result of the 2017 Tax Act, the Company revised its estimated annual effective rate to reflect the change in the U.S. federal statutory rate. The revised blended U.S. federal statutory tax rate for the fiscal year is 28%.

Measurement of certain income tax effects that can be reasonably estimated (provisional amounts)

During the second quarter ended December 31, 2017, the Company recorded a one-time net charge of $46.0 million within its income tax provision as a provisional estimate of the net accounting impact of the 2017 Tax Act in accordance with SAB 118. The net charge is comprised of the following: (i) expense of $48.7 million related to the mandatory transition tax for deemed repatriation of deferred foreign income, $8.7 million of which the Company expects to pay over an 8-year period after considering the use of certain net operating losses and foreign tax credits, and certain limitations on executive compensation; (ii) an additional $9.5 million charge relating to the impact of provisional changes in the Company's intentions with respect to future repatriation of undistributed earnings from non-U.S. subsidiaries and (iii) a benefit of $12.2 million related to a revaluation of the Company’s deferred tax assets and liabilities. The one-time net charge, which was recorded on a provisional basis, increased the Company’s effective tax rate by 164% and 154% during the three-month and six-month periods ended December 31, 2017, respectively.

Given the significant complexity of the 2017 Tax Act, anticipated guidance from the U.S. Treasury concerning implementation of the 2017 Tax Act, and the potential for additional guidance from the SEC or the FASB related to the 2017 Tax Act, the provisional estimates that the Company recorded may require adjustment during the measurement period. The provisional estimates were based on the Company’s present understanding of the 2017 Tax Act and other information available as of the time of the estimates, including assumptions and expectations about future events, such as its projected financial performance, and are subject to further refinement as additional information becomes available (including the Company’s actual full fiscal 2018 results of operations, as well as potential new or interpretative guidance issued by the SEC, the FASB, or the Internal Revenue Service) and the Company continues its analysis. The Company continues to analyze the changes to certain income tax deductions, assess calculations of earnings and profits in certain foreign subsidiaries, including whether those earnings are held in cash or other assets, and gather additional data to compute the full impact of the 2017 Tax Act on the Company’s deferred and current tax assets and liabilities.

Table of Contents

Measurement of certain income tax effects that cannot be reasonably estimated

Because of the complexity of the new GILTI tax rules, the Company continues to evaluate this provision of the 2017 Tax Act and the application of ASC 740. In accordance with ASC 740, the Company will make an accounting policy election of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the “period cost method”) or (2) factoring such amounts into the Company's measurement of its deferred taxes (the “deferred method”). The Company's selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing its global income to determine whether it expects to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Whether the Company expects to have future U.S. inclusions in taxable income related to GILTI depends on not only the Company's current structure and estimated future results of global operations, but also its intent and ability to modify its structure. Therefore, the Company has not made any adjustment related to potential GILTI tax in its financial statements and has not made a policy decision regarding whether to record deferred tax on GILTI.

Additionally, the Company continues to evaluate the potential impact of all other provisions, including but not limited to provisions regarding the FDII, BEAT, interest expense and certain employee expense deductions, as well as the state tax impact of the 2017 Tax Act. The Company is currently in the process of analyzing its structure and estimated future results and, as a result, is not yet able to reasonably estimate the effect of these provisions of the 2017 Tax Act.

Other Tax Matters

The Company accounts for income taxes in accordance with ASC ~~740 Income Taxes~~.740. Generally, fluctuations in the effective tax rate are primarily due to changes in U.S. and non-U.S. pretax income resulting from the Company’s business mix and changes in the tax impact of special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. Such discrete items include, but are not limited to, changes in foreign statutory tax rates, the amortization of certain assets, and the tax impact of changes in its ASC 740 unrecognized tax benefit reserves. In the normal course of business, the Company is subject to examination by taxing authorities around the world, including such major jurisdictions as the United States, Germany, France, and the United Kingdom. The Company is no longer subject to new non-U.S. income tax examinations for years prior to fiscal year ~~2007.~~2008. Under the terms of the 2007 purchase agreement by which the selling stockholders acquired their interest in the Company, the Company is indemnified by its former owner for tax liabilities that may arise after the 2007 purchase that relate to tax periods prior to April 10, 2007. The indemnification agreement applies to, among other taxes, any and all federal, state and international income-based taxes as well as related interest and penalties. As of ~~March~~December 31, 2017 and June 30, ~~2016,~~2017, approximately ~~$0.8~~$0.7 million and ~~$1.7~~$0.8 million, respectively, of unrecognized tax benefit are subject to indemnification by the Company's former owner.

ASC 740 includes guidance on the accounting for uncertainty in income taxes recognized in the financial statements. This standard provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolution of any related appeal or litigation process, based on the technical merits. As of ~~March~~December 31, 2017, the Company had a total of ~~$61.5~~$52.5 million of unrecognized tax benefits. A reconciliation of its reserves for uncertain tax positions, excluding accrued interest and penalties, for ~~March~~December 31, 2017 is as follows:

(Dollars in millions)
Balance at June 30, 2016 $ 61.5
Additions for tax positions of current year 1.6
Reductions for tax positions of prior years (1.4 )
Lapse of the applicable statute of limitations (0.2 )
Balance at March 31, 2017 $ 61.5



(Dollars in millions)
Balance at June 30, 2017	$	52.5
Additions for tax positions of current year	—
Balance at December 31, 2017	$	52.5

As of ~~March~~December 31, 2017 and June 30, ~~2016,~~2017, the Company had a total of ~~$67.2~~$57.5 million and $~~67.1~~57.5 million, respectively, of uncertain tax positions (including accrued interest and penalties). As of these dates, ~~$45.7~~$41.4 million and $~~45.7~~41.4 million, respectively, represent the amount of unrecognized tax benefits, which, if recognized, would favorably affect the effective income tax rate. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of ~~March~~December 31, 2017 and June 30, ~~2016,~~2017, the Company has approximately ~~$5.7~~$5.0 million and $~~5.6~~5.0 million, respectively, of accrued interest and penalties related to uncertain tax positions. As of these dates, the portion of such interest and penalties subject to indemnification by its former owner is ~~$1.7~~$1.5 million and $~~2.1~~1.7 million, respectively.

2023

Table of Contents


~~10.~~11.	EMPLOYEE RETIREMENT BENEFIT PLANS

Components of the Company’s net periodic benefit costs are as follows:


	Three Months Ended March 31,						Nine Months Ended March 31,						Three Months Ended December 31,						Six Months Ended December 31,
(Dollars in millions)	2017			2016			2017			2016			2017			2016			2017			2016
Components of net periodic benefit cost:
Service cost	$	0.8		$	0.7		$	2.4		$	2.1		$	0.9		$	0.8		$	1.8		$	1.6
Interest cost	1.6			2.6			4.9			8.0			1.8			1.6			3.6			3.3
Expected return on plan assets	(2.7		)	(2.4		)	(8.1		)	(7.5		)	(2.9		)	(2.6		)	(5.8		)	(5.4		)
Amortization ⁽¹⁾	1.1			0.6			3.2			2.0			0.6			1.0			1.2			2.1
Net amount recognized	$	0.8		$	1.5		$	2.4		$	4.6		$	0.4		$	0.8		$	0.8		$	1.6


(1)	Amount represents the amortization of unrecognized actuarial gains/(losses).

As previously disclosed, the Company notified the trustees of a multi-employer pension plan of its withdrawal from participation in such plan in fiscal 2012. The actuarial review process administered by the plan trustees ended in fiscal 2015. The liability reported reflects the present value of the Company's expected future long-term obligations. The estimated discounted value of the projected contributions related to such plans was ~~$39.2~~$39.1 million as of ~~March~~December 31, 2017 and ~~$39.3 million as of~~ June 30, ~~2016~~2017 and is included within pension liability on the consolidated balance sheets. The annual cash impact associated with the Company's obligation in such plan approximates $1.7 million per year.


~~11.~~12.	EQUITY AND ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)

Description of Capital Stock

The Company is authorized to issue 1,000,000,000 shares of common stock, par value $0.01 per share, and 100,000,000 shares of preferred stock, par value $0.01 per share. In accordance with the Company's amended and restated certificate of incorporation, each share of common stock has one vote, and the common stock votes together as a single class.

Public Stock Offering

On September 29, 2017, the Company completed a public offering of its common stock (the "Equity Offering"), pursuant to which the Company sold 7.4 million shares, including shares sold pursuant to an exercise of the underwriters' over-allotment option, at a price of $39.10 per share, before underwriting discounts and commissions. Net of these discounts and commissions and other offering expenses, the Company obtained total proceeds from the Equity Offering, including the over-allotment exercise, of $277.8 million. The net proceeds of the Equity Offering, after payment of the discount and related fees and expenses, were used to fund a portion of the consideration for the Catalent Indiana acquisition due at its closing.

Outstanding Stock

Shares outstanding include shares of unvested restricted stock. Unvested restricted stock included in reportable shares outstanding was 0.3 million shares as of December 31, 2017. Shares of unvested restricted stock are excluded from our calculation of basic weighted average shares outstanding, but their dilutive impact is added back in the calculation of diluted weighted average shares outstanding.

Stock Repurchase Program

On October 29, 2015, the Company’s Board of Directors authorized a share repurchase program to use up to $100.0 million to repurchase shares of its outstanding common stock. Under the program, the Company is authorized to repurchase shares through open market purchases, privately negotiated transactions, or otherwise as permitted by applicable federal securities laws. There has been no purchase pursuant to this program as of ~~March~~December 31, 2017.

Table of Contents

Accumulated ~~other comprehensive income/(loss)~~Other Comprehensive Income/(Loss)

The components of the changes in the cumulative translation adjustment, minimum pension liability and available for sale investment for the three and ~~nine~~six months ended ~~March~~December 31, 2017 and ~~March~~December 31, 2016 are presented below.


	Three Months Ended March 31,						Nine Months Ended March 31,						Three Months Ended December 31,						Six Months Ended December 31,
(Dollars in millions)	2017			2016			2017			2016			2017			2016			2017			2016
Foreign currency translation adjustments:
Net investment hedge	$	(13.9	)	$	(4.1	)	$	(3.9	)	$	(1.6	)	$	(3.9	)	$	13.6		$	(21.5	)	$	10.0
Long-term intercompany loans	3.0			(18.3		)	(17.9		)	(38.1		)	(2.3		)	(13.3		)	11.2			(20.9		)
Translation adjustments	30.6			5.0			(18.6		)	(43.2		)	(5.2		)	(59.8		)	30.9			(49.2		)
Total foreign currency translation adjustment, pretax	19.7			(17.4		)	(40.4		)	(82.9		)	(11.4		)	(59.5		)	20.6			(60.1		)
Tax expense/(benefit)	(4.9		)	(1.5		)	(1.2		)	(0.6		)	2.0			4.9			(4.1		)	3.7
Total foreign currency translation adjustment, net of tax	$	24.6		$	(15.9	)	$	(39.2	)	$	(82.3	)	$	(13.4	)	$	(64.4	)	$	24.7		$	(63.8	)

Net change in minimum pension liability
Net gain/(loss) recognized during the period	1.1			0.8			3.2			2.2			0.6			1.0			1.2			2.1
Total pension, pretax	1.1			0.8			3.2			2.2			0.6			1.0			1.2			2.1
Tax expense/(benefit)	0.3			0.2			0.9			0.6			0.1			0.3			0.3			0.6
Net change in minimum pension liability, net of tax	$	0.8		$	0.6		$	2.3		$	1.6		$	0.5		$	0.7		$	0.9		$	1.5

Net change in available for sale investment:
Net gain/(loss) recognized during the period	0.8			—			25.3			—			(3.6		)	24.5			(8.8		)	24.5
Total available for sale investment, pretax	0.8			—			25.3			—			(3.6		)	24.5			(8.8		)	24.5
Tax expense/(benefit)	(0.2		)	—			9.0			—			(0.6		)	9.2			(2.4		)	9.2
Net change in available for sale investment, net of tax	$	1.0		$	—		$	16.3		$	—		$	(3.0	)	$	15.3		$	(6.4	)	$	15.3

For the three months ended ~~March~~December 31, 2017, the changes in accumulated other comprehensive income, net of tax by component are as follows:


(Dollars in millions)	Foreign Exchange Translation Adjustments			Pension and Other Post-Retirement Adjustments			Available for Sale investment Adjustments		Total			Foreign Exchange Translation Adjustments			Pension and Liability Adjustments			Available for Sale Investment Adjustments			Total
Balance at December 31,2016	$	(312.6	)	$	(55.4	)	$	15.3	$	(352.7	)
Balance at September 30, 2017												$	(242.6	)	$	(43.5	)	$	7.1		$	(279.0	)
Other comprehensive income/(loss) before reclassifications	24.6			—			1.0		25.6			(13.4		)	—			(3.0		)	(16.4		)
Amounts reclassified from accumulated other comprehensive income	—			0.8			—		0.8			—			0.5			—			0.5
Net current period other comprehensive income (loss)	24.6			0.8			1.0		26.4			(13.4		)	0.5			(3.0		)	(15.9		)
Balance at March 31, 2017	$	(288.0	)	$	(54.6	)	$	16.3	$	(326.3	)
Balance at December 31, 2017												$	(256.0	)	$	(43.0	)	$	4.1		$	(294.9	)

2225

Table of Contents

For the ~~nine~~six months ended ~~March~~December 31, 2017, the changes in accumulated other comprehensive income, net of tax by component are as follows:


(Dollars in millions)	Foreign Exchange Translation Adjustments			Pension and Other Post-Retirement Adjustments			Available for Sale investment Adjustments		Total			Foreign Exchange Translation Adjustments			Pension and Liability Adjustments			Available for Sale investment Adjustments			Total
Balance at June 30, 2016	$	(248.8	)	$	(56.9	)	$	—	$	(305.7	)
Balance at June 30, 2017												$	(280.7	)	$	(43.9	)	$	10.5		$	(314.1	)
Other comprehensive income/(loss) before reclassifications	(39.2		)	—			16.3		(22.9		)	24.7			—			(6.4		)	18.3
Amounts reclassified from accumulated other comprehensive income	—			2.3			—		2.3			—			0.9			—			0.9
Net current period other comprehensive income (loss)	(39.2		)	2.3			16.3		(20.6		)	24.7			0.9			(6.4		)	19.2
Balance at March 31, 2017	$	(288.0	)	$	(54.6	)	$	16.3	$	(326.3	)
Balance at December 31, 2017												$	(256.0	)	$	(43.0	)	$	4.1		$	(294.9	)

The Company held an investment in a specialty pharmaceutical company, which was treated as a cost method investment prior to the second quarter of fiscal 2017. In the second quarter of fiscal 2017, the specialty pharmaceutical company became publicly traded after an initial public offering and as a result the Company recognized an unrealized gain on the investment of $15.3 million, net of tax. This amount is reflected in accumulated other comprehensive income.


~~12.~~13.	COMMITMENTS AND CONTINGENCIES

During the period November 2015 through April 2016, the primary French drug regulatory agency temporarily suspended operations at the Company’s softgel manufacturing facility in Beinheim, France, subject to exemptions for certain types of operations, and theThe Company continues to receive and resolve claims stemming ~~therefrom.~~from a prior, temporary, regulatory suspension of one of our manufacturing facilities. To date, more than 2530 customers of the facility have presented claims against the Company for alleged losses, including lost profits and other types of indirect or consequential damages that they have allegedly suffered due to the temporary suspension, or have reserved their right to do so subsequently. The Company is unable to estimate at this time either the total value of claims that are reasonably possible to be asserted with respect to this matter or the likely cost to resolve them, although (a) as of the end of ~~the third quarter of fiscal~~December 31, 2017, the Company recorded $3.2 million for claim amounts that the Company deemed to be both probable and reasonably estimable but is not currently in a position to record under GAAP any insurance recovery with respect to such costshas settled 18 customer claims and (b) certain remaining customers have presented the Company with support for other claims having an aggregate claim value of approximately ~~$37~~$4.0 million. ~~It is noteworthy that, to~~To date, none of the asserted claims takes into account limitations of liability in the contracts governing these claims or any other defense that the Company may assert. In addition, the Company may have insurance for additional costs it may incur as a result of such claims, subject to various deductibles and other limitations, but there can be no assurance as to the aggregate amount or timing of insurance recoveries against any such costs. ~~Changes to the operations of the Beinheim facility to address the issues leading to the suspension have increased the cost and therefore may affect the profitability of its operation.~~

From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will have a material adverse effect on the Company’s financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.

From time to time, the Company receives subpoenas or requests for information relating to the business practices and activities of customers or suppliers from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties engaged in patent infringement, antitrust, tort, and other litigation. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred. The Company expects to incur costs in future periods in connection with future requests.


~~13.~~14.	SEGMENT INFORMATION

~~As discussed in Note 1, the~~The Company conducts its business within the following operating segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Company evaluates the performance of its segments based on segment earnings before noncontrolling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax (benefit)/expense, and depreciation and amortization (“Segment EBITDA”). EBITDA from continuing

~~Table of Contents~~

operations is consolidated earnings from continuing operations before interest expense, income tax (benefit)/expense, depreciation and amortization and is adjusted for the income or loss attributable to noncontrolling interest. ~~The Company’s presentation of~~ Segment EBITDA and EBITDA from continuing operations are not ~~prepared~~defined in ~~accordance with~~ GAAP and may not be comparable to similarly titled measures used by other companies.

Table of Contents

~~All prior period comparative segment information has been restated to reflect the current reportable segments in accordance with ASC 280 Segment Reporting~~. The following tables include net revenue and Segment EBITDA during the three and ~~nine~~six months ended ~~March~~December 31, 2017 and ~~March~~December 31, 2016:

Three Months Ended
March 31, Nine Months Ended
March 31,
(Dollars in millions) 2017 2016 2017 2016
Softgel Technologies
Net revenue $ 209.9
$ 185.1
$ 598.2
$ 550.2
Segment EBITDA 51.4
35.4
125.3
104.8
Drug Delivery Solutions
Net revenue 234.6
190.5
639.9
568.2
Segment EBITDA 59.5
39.9
151.5
139.5
Clinical Supply Services
Net revenue 97.5
71.5
249.5
226.0
Segment EBITDA 15.7
12.1
37.8
39.5
Inter-segment revenue elimination (9.4 ) (9.1 ) (29.1 ) (28.5 )
Unallocated Costs ⁽¹⁾
(32.8 ) (17.1 ) (72.9 ) (43.9 )
Combined Totals:
Net revenue $ 532.6
$ 438.0
$ 1,458.5
$ 1,315.9

EBITDA from continuing operations $ 93.8
$ 70.3
$ 241.7
$ 239.9

~~Table of Contents~~



	Three Months Ended December 31,						Six Months Ended December 31,
(Dollars in millions)	2017			2016			2017			2016
Softgel Technologies
Net revenue	$	228.1		$	201.9		$	447.8		$	388.3
Segment EBITDA	50.1			43.4			85.2			73.9
Drug Delivery Solutions
Net revenue	285.4			214.0			511.2			405.3
Segment EBITDA	81.1			50.0			128.5			92.0
Clinical Supply Services
Net revenue	108.7			77.0			218.4			152.0
Segment EBITDA	19.0			11.6			35.7			22.1
Inter-segment revenue elimination	(15.9		)	(9.2		)	(27.2		)	(19.7		)
Unallocated Costs ⁽¹⁾	(48.2		)	(19.8		)	(82.2		)	(40.1		)
Combined Totals:
Net revenue	$	606.3		$	483.7		$	1,150.2		$	925.9

EBITDA from continuing operations	$	102.0		$	85.2		$	167.2		$	147.9


(1)	Unallocated costs ~~includes~~include restructuring and special items, equity-based compensation, ~~certain acquisition-related costs,~~ impairment charges, certain other corporate directed costs, ~~certain customer claim expenses related to the Beinheim facility suspension~~ and other costs that are not allocated to the segments as follows:


	Three Months Ended March 31,						Nine Months Ended March 31,						Three Months Ended December 31,						Six Months Ended December 31,
(Dollars in millions)	2017			2016			2017			2016			2017			2016			2017			2016
Impairment charges and gain/(loss) on sale of assets	$	(1.8	)	$	0.3		$	(2.3	)	$	(0.8	)	$	(4.2	)	$	(0.5	)	$	(4.2	)	$	(0.5	)
Equity compensation	(4.6		)	(3.6		)	(16.4		)	(8.7		)	(8.5		)	(4.9		)	(15.5		)	(11.8		)
Restructuring and other special items ⁽²⁾	(8.5		)	(9.5		)	(21.6		)	(15.7		)	(11.9		)	(7.2		)	(24.2		)	(13.1		)
Noncontrolling interest	—			—			—			0.3
Other income/(expense), net ⁽³⁾	(7.3		)	4.2			(3.4		)	7.1			(13.6		)	1.8			(19.3		)	3.9
Non-allocated corporate costs, net	(10.6		)	(8.5		)	(29.2		)	(26.1		)	(10.0		)	(9.0		)	(19.0		)	(18.6		)
Total unallocated costs	$	(32.8	)	$	(17.1	)	$	(72.9	)	$	(43.9	)	$	(48.2	)	$	(19.8	)	$	(82.2	)	$	(40.1	)


(2)	Segment results do not include restructuring and ~~other costs associated with certain customer claim expenses related to the Beinheim facility suspension and~~ certain acquisition-related costs.


(3)	~~Amounts primarily relate~~Refer to Note 7 for details of financing charges and foreign currency translation ~~gains and losses during all periods presented.~~adjustments recorded within other income/(expense), net.

Provided below is a reconciliation of EBITDA from continuing operations to earnings/(loss) from continuing ~~operations, the closest related measure prepared in accordance with GAAP:~~operations:


	Three Months Ended March 31,				Nine Months Ended March 31,				Three Months Ended December 31,					Six Months Ended December 31,
(Dollars in millions)	2017		2016		2017		2016		2017			2016		2017			2016
Earnings from continuing operations	$	26.0	$	10.7	$	48.0	$	53.1
Earnings/(loss) from continuing operations									$	(21.9	)	$	17.4	$	(18.1	)	$	22.0
Depreciation and amortization	36.5		34.8		107.8		105.5		46.8			35.5		85.8			71.3
Interest expense, net	22.6		21.7		67.5		66.7		27.2			22.8		51.5			44.9
Income tax (benefit)/expense	8.7		3.1		18.4		14.3
Noncontrolling interest	—		—		—		0.3
Income tax expense/(benefit)									49.9			9.5		48.0			9.7
EBITDA from continuing operations	$	93.8	$	70.3	$	241.7	$	239.9	$	102.0		$	85.2	$	167.2		$	147.9

Table of Contents

The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements:


(Dollars in millions)	March 31, 2017			June 30, 2016			December 31, 2017			June 30, 2017
Assets
Softgel Technologies	$	1,590.7		$	1,446.4		$	1,538.4		$	1,631.8
Drug Delivery Solutions	1,560.7			1,475.7			2,650.5			1,639.0
Clinical Supply Services	595.4			578.9			620.3			596.2
Corporate and eliminations	(461.6		)	(409.9		)	(422.1		)	(412.7		)
Total assets	$	3,285.2		$	3,091.1		$	4,387.1		$	3,454.3

~~Table of Contents~~


~~14.~~15.	SUPPLEMENTAL BALANCE SHEET INFORMATION

Supplementary balance sheet information at ~~March~~December 31, 2017 and June 30, ~~2016~~2017 is detailed in the following tables.

Inventories

Work-in-process and finished goods inventories include raw materials, labor, and overhead. Total inventories consist of the following:


(Dollars in millions)	March 31, 2017			June 30, 2016			December 31, 2017			June 30, 2017
Raw materials and supplies	$	113.5		$	88.7		$	134.3		$	107.5
Work-in-process	41.8			30.7			29.3			42.8
Finished goods	55.1			55.2			69.9			56.7
Total inventories, gross	210.4			174.6			233.5			207.0
Inventory reserve	(16.5		)	(19.8		)
Inventory cost adjustment							(20.8		)	(22.1		)
Inventories	$	193.9		$	154.8		$	212.7		$	184.9

Prepaid expenses and other

Prepaid expenses and other current assets consist of the following:


(Dollars in millions)	March 31, 2017		June 30, 2016		December 31, 2017		June 30, 2017
Prepaid expenses	$	22.4	$	29.3	$	19.0	$	12.3
Spare parts supplies	11.7		10.8		11.4		11.8
Short term investments	—		7.0
Long term tax asset (current portion) ⁽¹⁾	—		6.8
Prepaid income tax					10.5		11.5
Non-US value added tax					19.9		16.0
Available for sale investment	27.6		—		9.8		18.6
Other current assets	29.0		35.1		34.8		27.6
Prepaid expenses and other	$	90.7	$	89.0	$	105.4	$	97.8

(1) The Company transferred certain intellectual property assets between jurisdictions in the year ended June 30, 2016, resulting in a deferred tax charge which will be amortized over the remaining 10-year useful life

Table of ~~the assets. The Company adopted~~ ~~ASU 2016-16, Accounting for Income Taxes: Intra-Entity Asset Transfers of Assets Other than Inventory~~ ~~effective July 1, 2016 and subsequently adjusted the long-term tax asset. Refer to Note 1 for further information.~~Contents

Property, plant, and equipment, net

Property, plant, and equipment, net consist of the following:

(Dollars in millions) March 31,
2017 June 30,
2016
Land, buildings, and improvements $ 720.8
$ 649.6
Machinery, equipment, and capitalized software 804.8
757.1
Furniture and fixtures 10.1
9.9
Construction in progress 125.3
134.1
Property, plant, and equipment, at cost 1,661.0
1,550.7
Accumulated depreciation (692.1 ) (644.9 )
Property, plant, and equipment, net $ 968.9
$ 905.8

~~Table of Contents~~



(Dollars in millions)	December 31, 2017			June 30, 2017
Land, buildings, and improvements	$	894.2		$	735.2
Machinery, equipment, and capitalized software	944.1			825.0
Furniture and fixtures	13.5			10.1
Construction in progress	179.9			137.4
Property, plant, and equipment, at cost	2,031.7			1,707.7
Accumulated depreciation	(775.5		)	(711.8		)
Property, plant, and equipment, net	$	1,256.2		$	995.9

Other accrued liabilities

Other accrued liabilities consist of the following:


(Dollars in millions)	March 31, 2017		June 30, 2016		December 31, 2017		June 30, 2017
Accrued employee-related expenses	$	82.9	$	82.8	$	72.6	$	96.4
Restructuring accrual	3.9		6.1		3.0		5.9
Accrued interest	6.2		0.1		5.6		0.9
Deferred revenue and fees	59.4		46.2		88.1		84.9
Accrued income tax	27.6		38.8		22.2		24.7
Other accrued liabilities and expenses	48.8		45.8		58.3		68.4
Other accrued liabilities	$	228.8	$	219.8	$	249.8	$	281.2

2729

Table of Contents


ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Company

We are the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer and animal health products. Our oral, injectable, and respiratory delivery technologies provide delivery solutions across the full diversity of the pharmaceutical industry, including small molecules, ~~large molecule~~ biologics, and consumer and animal health products. Through our extensive capabilities and deep expertise in product development, we help our customers take products to market faster, including nearly half of new drug products approved by the ~~Food and Drug Administration (“FDA”)~~FDA in the last decade. Our advanced delivery technology platforms, which include those in our Softgel Technologies and our Drug Delivery Solutions segments, our proven

formulation, manufacturing and regulatory expertise and our broad and deep intellectual property enable our customers and their patients' needs to develop more products and better treatments for patients and consumers. Across both development and delivery, our commitment to reliably supply our customers’ ~~and their patients'~~ needs is the foundation for the value we provide; annually, we produce ~~more than 70~~approximately 72 billion doses for nearly 7,000 customer products or approximately one in every twenty doses of such products taken each year by patients and consumers around the world. We believe that through our investments in growth-enabling capacity and capabilities, our ongoing focus on operational and quality excellence, the sales of existing customer products, the introduction of new customer products, our innovation activities and patents, and our entry into new markets, we will continue to benefit from attractive and differentiated margins, and realize the growth potential from these areas.

In the fourth quarter of fiscal 2016, we engaged in a business reorganization to better align our internal business unit structure with our strategy to “follow the molecule” by providing solutions to our customers across all phases of the product lifecycle. Under the revised structure, we have created a Drug Delivery Solutions (“DDS”) operating segment, which encompasses all of our modified release technologies; prefilled syringes and other injectable formats; blow-fill seal unit dose development and manufacturing; biologic cell line development; analytical services; micronization technologies; and other conventional oral dose forms under a single DDS management team. Additionally, as part of the re-alignment, we have created a stand-alone Clinical Supply Services (“CSS”) operating segment and management team with a sole focus on providing global clinical supply chain management services that aim to speed our customers' drugs to market. Further, as a result of the business unit re-alignment, our Softgel Technologies business now reports as a distinct operating segment. Our operating segments are the same as our reporting segments. All prior period comparative segment information has been restated to reflect the current reportable segments in accordance with ~~ASC 280 Segment Reporting.~~

Critical Accounting Policies and Estimates

We prepare our financial statements in accordance with GAAP. These standards require management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset impairment, income taxes, derivative financial instruments, self-insurance accruals, loss contingencies and restructuring charge reserves. Actual amounts may differ from these estimated amounts.

There was no material change to our critical accounting policies or in the underlying accounting assumptions and estimates from those described in our fiscal year ~~2016~~2017 Annual Report on Form 10-K, other than recently adopted accounting principles ~~for the issuance of~~ ~~ASU 2016-16, Accounting for Income Taxes: Intra-Entity Asset Transfers of Assets Other than Inventory~~ as disclosed in Note 1 to the unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, which adoption had no material impact on net earnings.

Non-GAAP Performance Metrics

Use of EBITDA from continuing operations

Management measures operating performance based on consolidated earnings from continuing operations before interest expense, expense/(benefit) for income taxes and depreciation and amortization ~~and is adjusted for the income or loss attributable to noncontrolling interest~~ (“EBITDA from continuing operations”). EBITDA from continuing operations is not defined under GAAP and is not a measure of operating income, operating performance or liquidity presented in accordance with GAAP and is subject to important limitations.

We believe that the presentation of EBITDA from continuing operations enhances an investor’s understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business and use this measure for business

~~Table of Contents~~

planning purposes. In addition, given the significant investments that we have made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of our cost structure. We believe that EBITDA from continuing operations will provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense. We present EBITDA from continuing operations in order to provide supplemental information that we consider relevant for the readers of our consolidated financial statements, and such information is not meant to replace or supersede GAAP measures. Our definition of EBITDA from continuing operations may not be the same as similarly titled measures used by other companies. The most directly comparable GAAP measure to EBITDA from continuing operations is earnings/(loss) from continuing operations. Included in this report is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations.

In addition, we evaluate the performance of our segments based on segment earnings before noncontrolling interest, other (income)/expense, impairments, restructuring costs, interest expense, income tax expense/(benefit), and depreciation and amortization (“Segment EBITDA”).

Table of Contents

Use of Constant Currency

As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a constant currency basis as one measure to evaluate our performance. In this Quarterly Report on Form 10-Q, we compute constant currency by calculating current-year results using prior-year foreign currency exchange rates. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Other Non-GAAP Measures

Organic revenue growth and segment EBITDA growth are useful measures calculated by the Company to explain the underlying results and trends in the business. Organic revenue growth and segment EBITDA growth are measures used to show current year sales and earnings from existing operations and include joint ventures and revenue from product participation related activities entered into within the year. Organic revenue growth and segment EBITDA growth exclude the impact of foreign currency, acquisitions of operating or legal entities and divestitures within the year. These measures should be considered in addition to, not as a substitute for, performance measures reported in accordance with GAAP. These measures, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Three Months Ended December 31, 2017 Compared to the Three Months Ended December 31, 2016

Results for three months ended December 31, 2017 compared to three months ended December 31, 2016 were as follows:



	Three Months Ended December 31,						FX impact		Constant Currency Increase/(Decrease)
(Dollars in millions)	2017			2016					Change $			Change %
Net revenue	$	606.3		$	483.7		$	17.0	$	105.6		22	%
Cost of sales	418.9			335.8			12.7		70.4			21	%
Gross margin	187.4			147.9			4.3		35.2			24	%
Selling, general and administrative expenses	114.3			96.2			1.1		17.0			18	%
Impairment charges and (gain)/loss on sale of assets	4.2			0.5			0.1		3.6			*
Restructuring and other	0.1			3.3			—		(3.2		)	(97	)%
Operating earnings	68.8			47.9			3.1		17.8			37	%
Interest expense, net	27.2			22.8			0.3		4.1			18	%
Other (income)/expense, net	13.6			(1.8		)	1.4		14.0			*
Earnings from continuing operations, before income taxes	28.0			26.9			1.4		(0.3		)	(1	)%
Income tax expense/(benefit)	49.9			9.5			—		40.4			*
Net earnings/(loss)	$	(21.9	)	$	17.4		$	1.4	$	(40.7	)	*

*Percentage not meaningful

Net Revenue

Net revenue increased $105.6 million, or 22%, compared to the three months ended December 31, 2016, excluding the impact of foreign exchange. Net revenue increased 14% as a result of acquisitions. We acquired Cook Pharmica LLC (now doing business as Catalent Indiana, LLC, "Catalent Indiana") in October 2017, which is included within our Drug Delivery Solutions segment and Accucaps Industries Limited ("Accucaps") in February 2017, which is in our Softgel Technologies segment. Excluding the impact of acquisitions, net revenue increased by 8%, primarily due to increased volume in lower-margin comparator sourcing volume and our storage and distribution business within our Clinical Supply Services segment, timing of a standard maintenance shut-down at our European sterile pre-filled syringe facility and increased volume within our biologics offerings within our Drug Delivery Solutions segment.

2931

Table of Contents

~~Results of Operations~~Gross Margin

~~Three Months Ended March 31, 2017~~ ~~Compared to the~~ ~~Three Months Ended March 31, 2016~~

Three Months Ended
March 31, FX impact Constant Currency Increase/(Decrease)
(Dollars in millions) 2017 2016
Change $ Change %
Net revenue $ 532.6
$ 438.0
$ (13.3 ) $ 107.9
25 %
Cost of sales 365.2
311.8
(7.9 ) 61.3
20 %
Gross margin 167.4
126.2
(5.4 ) 46.6
37 %
Selling, general and administrative expenses 100.9
93.4
(1.3 ) 8.8
9 %
Impairment charges and (gain)/loss on sale of assets 1.8
(0.3 ) (0.1 ) 2.2
*
Restructuring and other 0.1
1.8
0.5
(2.2 ) *
Operating earnings 64.6
31.3
(4.5 ) 37.8
*
Interest expense, net 22.6
21.7
(0.5 ) 1.4
6 %
Other (income)/expense, net 7.3
(4.2 ) (0.8 ) 12.3
*
Earnings from continuing operations, before income taxes 34.7
13.8
(3.2 ) 24.1
*
Income tax expense 8.7
3.1
(0.4 ) 6.0
*
Net earnings 26.0
10.7
(2.8 ) 18.1
*
Less: Net earnings/(loss) attributable to noncontrolling
interest, net of tax —
—
—
—
*
Net earnings attributable to Catalent $ 26.0
$ 10.7
$ (2.8 ) $ 18.1
*

*Percentage not meaningful

~~Net Revenue~~

~~Net revenue~~Gross margin increased ~~$107.9~~$35.2 million, or ~~25%~~24%, as compared to the three months ended ~~March~~December 31, 2016, excluding the impact of foreign exchange. ~~The increase in net revenue was driven by~~Gross margin increased ~~sales~~ across all three reportable segments led primarily by our Drug Delivery Solutions segment. The increase in net revenue was primarily due to favorable end market customer demand for certain offerings within our oral delivery solutions platform and our biologics offerings within our Drug Delivery Solutions segment. Net revenue also increased due to increased lower-margin comparator sourcing volume within our Clinical Supply Services segment and increased end market volume demand for our higher margin prescription products in Europe within our Softgel Technologies segment compared to lower production levels related to the temporary suspension of operations in the prior fiscal year. In addition, we acquired Pharmatek in September 2016 and Accucaps in February 2017, which increased net revenue within our Drug Delivery Solutions and our Softgel Technologies segments, respectively.

~~Gross Margin~~

~~Gross margin increased $46.6 million, or 37%, as compared to the three months ended March 31, 2016, excluding the impact of foreign exchange,~~ primarily due to increased gross margin within our Drug Delivery Solutions segment driven primarily by increased demand and favorable mix relating to certain offerings within our oral delivery solutions platform and within our biologics offerings. In addition, our Softgel Technologies segment increased gross margin due to a favorable mix shift to higher margin prescription products.sales volumes as discussed above. On a ~~constant currency~~constant-currency basis, gross margin, as a percentage of revenue, increased ~~290~~50 basis points to ~~31.7%~~31.1% in the three months ended ~~March~~December 31, 2017, as compared to ~~28.8%~~30.6% in the prior year period. The increase was primarily due to a favorable mix shift to certain higher margin offerings within our oral delivery solutions and biologics offerings in our U.S. operations within our Drug Delivery Solutions ~~and~~segment, partially offset by a decrease in our product participation revenue within both our Softgel Technologies ~~segments as discussed above.~~

~~Table of Contents~~

segment and our Drug Delivery Solutions segment.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased ~~$8.8~~$17.0 million, or 9%18%, as compared to the three months ended ~~March~~December 31, 2016, excluding the impact of foreign exchange, primarily due to ~~incremental employee-related costs~~additional expenses from recently acquired companies of ~~approximately $3.0~~$9 million, which includes $5 million of ~~which $1.0~~incremental depreciation and amortization expense and $2 million ~~is attributable~~of employee related costs. Additionally, the three months ended December 31, 2017 includes one-time transaction fees of $2 million related to ~~an increase~~the acquisition of Catalent Indiana in our non-cash equity-based compensation plans. Other increases to employee-related cost included inflationary increases, certain employee relocation and recruiting costs and health and wellness costs. Equity-based compensation expense increased as a result of a change from a cash-based long-term incentive plan to an equity-based long-term incentive plan. In addition, selling,October 2017. Selling, general and administrative ~~expense~~expenses further increased approximately ~~$5.0~~$4 million ~~relating~~for non-cash equity based compensation driven by higher expense for certain performance based awards in the current period.

Impairment charges and (gain)/loss on sale of assets

Impairment charges and loss on sale of assets of $4.2 million includes the loss on sale of two Softgel Technologies segment manufacturing sites in the Asia Pacific region. The site divestitures were neither material individually or in aggregate to ~~incremental expense from our newly acquired entities, which included $2.0 million of integration costs.~~the segment or to the Company.

Restructuring and Other

Restructuring and other costs of $0.1 million for the three months ended ~~March~~December 31, 2017 decreased ~~$1.7~~$3.2 million compared to the three months ended ~~March~~December 31, ~~2016, excluding~~2016. Other costs in the ~~impact of foreign exchange. The~~ three months ended ~~March~~December 31, ~~2017~~2016, included ~~restructuring activities enacted~~claim resolution charges of $3.2 million (without regard to ~~improve cost efficiency and primarily~~possible future insurance recoveries), related to ~~employee severance expenses~~a previous temporary regulatory suspension at one of ~~$3.1 million offset with the recovery of previously recorded facility exit costs of $3.0 million associated with site closures completed in the previous year.~~our manufacturing facilities. Restructuring expense will vary period to period based on the level of ~~recent~~ acquisitions during the year and site consolidation efforts to further streamline the business.

Interest Expense, net

Interest expense, net of ~~$22.6~~$27.2 million for the three months ended ~~March~~December 31, 2017 increased by ~~$0.9~~$4.4 million, or 4%19%, compared to the three months ended ~~March~~December 31, 2016, primarily driven by an average higher level of outstanding debt ~~resulting from~~associated with the ~~euro-denominated 4.75% Senior Notes due 2024 (the "Notes") issued~~financing for the Catalent Indiana acquisition in ~~December 2016,~~October 2017, partially offset by principal payments on our term loans and an overall reduction in ~~December 2016 in~~ our interest rates on our senior secured credit facility as compared to the ~~prior~~prior-year period.

On October 18, 2017, we completed a private offering (the "Debt Offering") of $450 million aggregate principal amount of 4.875% senior unsecured notes due 2026 (the "USD Notes"). The USD Notes will mature on January 15, 2026, bear interest at the rate of 4.875% per annum, and are payable semi-annually in arrears on January 15 and July 15 of each year beginning on July 15, 2018. The net proceeds of the Debt Offering, after payment of the initial purchasers' discount and related fees and expenses, were used to fund a portion of the Catalent Indiana acquisition consideration at its closing.

Concurrent with the Debt Offering, we completed the Third Amendment (the "Third Amendment") to our Amended and Restated Credit Agreement (as amended, the "Credit Agreement"), which lowered the interest rate on U.S. dollar-denominated and euro-denominated term loans and the revolving credit facility and extended the maturity dates on the senior secured credit facilities by three years. The new applicable rate for U.S. dollar-denominated term loans decreased 0.50%, and the new applicable rate for euro-denominated term loans is LIBOR decreased 0.75%. The new applicable rate for the revolving loans decreased 1.25%.

Further, a component of the purchase price for the Catalent Indiana acquisition consists of $200 million in deferred purchase consideration payable in $50 million installments, on each anniversary of the closing date over a period of four years, which is accounted for as debt and includes a component of imputed interest expense.

On December ~~12,~~9, 2016, ~~Catalent Pharma Solutions, Inc. ("Operating Company"), our wholly owned subsidiary,~~we completed a private offering of €380.0 million aggregate principal ~~amount ($391 million U.S. dollar equivalent)~~ of 4.75% Senior Notes due 2024 (the "Euro Notes"). The Euro Notes will mature on December 15, 2024, bear interest at the ~~Notes. The proceeds~~rate of ~~the Notes were used to repay $200 million~~4.75% per annum and are payable semi-annually in arrears on June 15 and December 15 of outstanding borrowings on Operating Company's U.S. dollar denominated term loan, pay the $81 million then outstanding under its revolving credit facility, pay accrued and unpaid interest and certain fees and expenses associated with the offering, fund a previously announced acquisition, and provide cash for general corporate purposes. The net increase to our outstanding debt balance is $164 million as compared to June 30, 2016. Concurrent with the private offeringeach year.

Table of the Notes, we repriced the senior secured credit facilities to lower the interest rate on our U.S. dollar-denominated and euro-denominated term loans. The new applicable rate for the U.S. dollar-denominated term loans is 0.50% lower than the previous rate and the new applicable rate for the euro-denominated term loans is 0.75% lower than the previous rate.Contents

Other (Income)/Expense, net

Other expense was ~~$7.3~~$13.6 million for the three months ended ~~March~~December 31, 2017, compared to ~~$4.2~~$1.8 million of other income for the three months ended ~~March~~December 31, 2016. ~~Other~~The expense ~~for~~in the three months ended ~~March~~December 31, 2017 was primarily driven by $11.8 million of financing charges related to the USD Notes offering and the Third Amendment, and includes a $6.1 million charge for commitment fees paid during the first quarter of fiscal 2018 on a proposed bridge loan made available to us for the purpose of providing back-up financing to fund a portion of the Catalent Indiana acquisition purchase price (the "Bridge Facility").

The three months ended December 31, 2016 of $1.8 million was primarily driven by non-cash net ~~losses~~gains of ~~$7.3~~$5.3 million related to foreign currency translation, ~~compared~~partially offset by $4.3 million of financing charges related to ~~foreign currency non-cash net gains~~the December 2016 private offering of ~~$3.6 million in~~ the ~~prior year.~~Euro Notes and repricing and partial paydown of our term loans.

Provision/(Benefit) for Income Taxes

During the second quarter ended December 31, 2017, we recorded a one-time net charge of $46.0 million within our income tax provision as a provisional estimate of the net accounting impact of the 2017 Tax Act in accordance with Staff Accounting Bulletin No. 118 issued by the staff of the SEC ("SAB 118"), of which $48.7 million million related to the mandatory transition tax for deemed repatriation of deferred foreign income, $8.7 million of which we expect to pay over an 8-year period after considering the use of certain net operating losses and foreign tax credits, and certain limitations on executive compensation. The impact to our business resulting from the 2017 Tax Act, including related changes to our tax obligations and effective tax rate in future periods, as well as the one-time enactment-related charges recorded during the second quarter in fiscal 2018 on a provisional basis, are based on a reasonable estimate and are subject to change, and any change could differ materially from our current expectations. Further, there are certain effects of the 2017 Tax Act we cannot reasonably estimate as of the time of this filing, including (a) the Global Intangible Low Tax Income ("GILTI") rules, (b) the Foreign Derived Intangible Income ("FDII") deduction, (c) the Base Erosion Anti-Abuse Tax ("BEAT"), (d) provisions eliminating or reducing certain income tax deductions, such as interest expense, and certain employee expenses, and (e) the state tax impact of the 2017 Tax Act. As additional data is gathered, analyzed, and considered in context of the 2017 Tax Act and ASC 740, we may record additional or different tax charges in future periods during the measurement period.

Our provision for income taxes for the three months ended ~~March~~December 31, 2017 was ~~$8.7~~$49.9 million relative to earnings from continuing operations before income taxes of ~~$34.7~~$28.0 million. Our provision for income taxes for the three months ended ~~March~~December 31, 2016 was ~~$3.1~~$9.5 million relative to earnings from continuing operations before income taxes of ~~$13.8~~$26.9 million. The income tax provision for the current period is not comparable to the same period of the prior year due to the impact of the 2017 Tax Act, changes in pretax income over many jurisdictions, and the impact of discrete items. Generally, fluctuations in the effective tax rate are primarily due to changes in our geographic pretax income resulting from our business mix and changes in the tax impact of permanent differences, restructuring, other special items, and other discrete tax items, which may have unique tax implications depending on the nature of the item. Our effective tax rate at March 31, 2017 reflects benefits derived from operations outside the United States, which are generally taxed at lower rates than the U.S. statutory rate of 35% as well as the benefits of favorable tax rate changes.

3133

Table of Contents

Segment Review

Our results on a segment basis for the three months ended ~~March~~December 31, 2017 compared to the three months ended ~~March~~December 31, 2016 were as follows:


	Three Months Ended March 31,						FX impact			Constant Currency Increase/(Decrease)					Three Months Ended December 31,						FX impact			Constant Currency Increase/(Decrease)
(Dollars in millions)	2017			2016						Change $			Change %		2017			2016						Change $			Change %
Softgel Technologies
Net revenue	$	209.9		$	185.1		$	(1.3	)	$	26.1		14	%	$	228.1		$	201.9		$	7.1		$	19.1		9	%
Segment EBITDA	51.4			35.4			(1.0		)	17.0			48	%	50.1			43.4			1.1			5.6			13	%
Drug Delivery Solutions
Net revenue	234.6			190.5			(6.7		)	50.8			27	%	285.4			214.0			7.0			64.4			30	%
Segment EBITDA	59.5			39.9			(2.6		)	22.2			56	%	81.1			50.0			2.0			29.1			58	%
Clinical Supply Services
Net revenue	97.5			71.5			(5.4		)	31.4			44	%	108.7			77.0			3.7			28.0			36	%
Segment EBITDA	15.7			12.1			(1.6		)	5.2			43	%	19.0			11.6			1.0			6.4			55	%
Inter-segment revenue elimination	(9.4		)	(9.1		)	0.1			(0.4		)	4	%	(15.9		)	(9.2		)	(0.8		)	(5.9		)	64	%
Unallocated Costs ⁽¹⁾	(32.8		)	(17.1		)	0.4			(16.1		)	94	%
Combined Total
Unallocated costs ⁽¹⁾															(48.2		)	(19.8		)	(1.3		)	(27.1		)	*
Combined total
Net revenue	$	532.6		$	438.0		$	(13.3	)	$	107.9		25	%	$	606.3		$	483.7		$	17.0		$	105.6		22	%

EBITDA from continuing operations	$	93.8		$	70.3		$	(4.8	)	$	28.3		40	%	$	102.0		$	85.2		$	2.8		$	14.0		16	%

(1) Unallocated costs includes equity-based compensation, certain acquisition-related costs, impairment charges, certain other corporate directed costs, ~~certain customer claim expenses related to the temporary Beinheim facility suspension~~ and other costs that are not allocated to the segments as follows:


	Three Months Ended March 31,						Three Months Ended December 31,
(Dollars in millions)	2017			2016			2017			2016
Impairment charges and gain/(loss) on sale of assets	$	(1.8	)	$	0.3		$	(4.2	)	$	(0.5	)
Equity compensation	(4.6		)	(3.6		)	(8.5		)	(4.9		)
Restructuring and other special items ⁽²⁾	(8.5		)	(9.5		)	(11.9		)	(7.2		)
Other income/(expense), net ⁽³⁾	(7.3		)	4.2			(13.6		)	1.8
Non-allocated corporate costs, net	(10.6		)	(8.5		)	(10.0		)	(9.0		)
Total unallocated costs	$	(32.8	)	$	(17.1	)	$	(48.2	)	$	(19.8	)

(2) ~~Segment results do not~~Restructuring and other special items include ~~restructuring~~transaction and ~~other~~integration costs associated with ~~certain customer claim~~the acquisition of Catalent Indiana.

(3) Amounts for the three months ended December 31, 2017 include $11.8 million of financing expenses related to the ~~temporary Beinheim facility suspension~~offering of the USD Notes and ~~certain acquisition-related costs.~~

~~(3) Amounts primarily relate to foreign currency translation gains~~the Third Amendment and ~~losses~~include a $6.1 million charge for commitment fees paid during ~~all periods presented.~~the first quarter of fiscal 2018 on the Bridge Facility.

3234

Table of Contents

Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations:


	Three Months Ended March 31,				Three Months Ended December 31,
(Dollars in millions)	2017		2016		2017			2016
Earnings from continuing operations	$	26.0	$	10.7
Earnings/(loss) from continuing operations					$	(21.9	)	$	17.4
Depreciation and amortization	36.5		34.8		46.8			35.5
Interest expense, net	22.6		21.7		27.2			22.8
Income tax (benefit)/expense	8.7		3.1
Income tax expense/(benefit)					49.9			9.5
EBITDA from continuing operations	$	93.8	$	70.3	$	102.0		$	85.2

Softgel Technologies segment


	2017 vs. 2016				2017 vs. 2016
Factors Contributing to Year-Over-Year Change	Three Months Ended March 31,				Three Months Ended December 31,
	Net Revenue		Segment EBITDA		Net Revenue		Segment EBITDA
Organic revenue / Segment EBITDA	8	%	40	%
Revenue/Segment EBITDA without acquisitions / divestitures					(3	)%	4	%
Impact of acquisitions	6	%	8	%	12	%	9	%
Constant currency change	14	%	48	%	9	%	13	%
Foreign currency translation impact on reporting	(1	)%	(3	)%	4	%	2	%
Total % change	13	%	45	%	13	%	15	%

Softgel Technologies’ net revenue increased by ~~$26.1~~$19.1 million, or ~~14%~~9%, excluding the impact of foreign exchange, compared to the three months ended ~~March~~December 31, ~~2016,~~2016. Net revenue decreased 3%, excluding the impact of ~~foreign exchange,~~the Accucaps acquisition, primarily driven by ~~increased end market~~decreased profit participation revenue of 2% as compared to three months ended December 31, 2016. Excluding the reduction in product participation revenue, net revenue without acquisitions decreased 1% primarily driven by decreased end-market volume demand for prescription products in Europe, which included increased volume at our Beinheim facility of approximately $12.0 million, compared to lower production levels related to the temporary suspension of operations in the prior fiscal year. In addition, net revenue increased as a result of higher end-market volume demand for prescription products in North America, partially offset byand lower end-market volume demand for consumer health products in Latin America and Asia ~~Pacific.~~Pacific, partially offset with revenue generated by a historical contractual settlement.

Softgel Technologies' Segment EBITDA increased by ~~$17.0~~$5.6 million, or ~~48%~~13%, as compared to the three months ended ~~March~~December 31, 2016, excluding the impact of foreign ~~exchange,~~exchange. Segment EBITDA increased 4%, excluding the impact of the Accucaps acquisition. Excluding the reduction of product participation profit of 8%, segment EBITDA without acquisitions increased 12%, primarily ~~driven by~~related to the impact of a historical contractual settlement of 6% and a favorable shift in product mix ~~shift to~~within our consumer health products in Asia Pacific and within our prescription products increased volume and reduced cost at our Beinheim facility of approximately $9.0 million compared to lower production levels related to a temporary suspension in the prior fiscal year. Refer to Note 12 to the unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for further discussion.

On February 14, 2017, we acquired Accucaps Industries Limited ("Accucaps"), the Canada-based developer and manufacturer of over-the-counter (OTC), high potency and conventional pharmaceutical softgels. The acquisition will substantially complement Catalent’s global consumer health and prescription pharmaceutical softgel capabilities and capacity with the addition of a portfolio of products supplied to pharmaceutical companies in North ~~America, and two state-of-the-art facilities offering integrated softgel development, manufacturing and packaging, strengthening our ability to offer customers turnkey solutions.~~ America.

The net revenue and EBITDA impact to our Softgel Technologies segment from the Accucaps acquisition for the three months ended ~~March~~December 31, 2017 iswas an increase of 6%12% and 8%9%, respectively, as compared to the prior-year period.

In December 2017, we divested of two manufacturing sites in Asia Pacific operated within the Softgel Technologies segment in order to better streamline our global operations. The site divestitures were material neither individually nor in aggregate to the segment or to the Company.

Drug Delivery Solutions segment



	2017 vs. 2016
Factors Contributing to Year-Over-Year Change	Three Months Ended December 31,
	Net Revenue		Segment EBITDA
Revenue/Segment EBITDA without acquisitions	9	%	18	%
Impact of acquisitions	21	%	40	%
Constant currency change	30	%	58	%
Foreign currency translation impact on reporting	3	%	4	%
Total % Change	33	%	62	%

3335

Table of Contents

~~Drug Delivery Solutions segment~~

2017 vs. 2016
Factors Contributing to Year-Over-Year Change Three Months Ended
March 31,
Net Revenue Segment EBITDA
Organic revenue / Segment EBITDA 23 % 53 %
Impact of acquisitions 4 % 3 %
Constant currency change 27 % 56 %
Foreign currency translation impact on reporting (4 )% (7 )%
Total % Change 23 % 49 %

Net revenue in our Drug Delivery Solutions segment increased by ~~$50.8~~$64.4 million, or ~~27%~~30%, compared to the three months ended ~~March~~December 31, 2016, excluding the impact of foreign exchange. ~~Organic net revenue~~Revenue without acquisitions increased by ~~23%~~9%, driven primarily by timing of a standard maintenance shut-down at our European sterile pre-filled syringe facility of 6%, increased volume from our biologics offerings of 4%, partially offset by a decrease in product participation revenue of 1%.

Drug Delivery Solutions' segment EBITDA increased by $29.1 million, or 58%, compared to the three months ended December 31, 2016, excluding the impact of foreign exchange. Segment EBITDA without acquisitions increased by 18% primarily due to favorable ~~end customer~~absorption of cost and timing of a standard maintenance shut-down at our European sterile pre-filled syringe facility, increased volume from our biologics offerings, and a favorable shift in end-customer demand ~~for~~to certain higher margin offerings primarily in our U.S. operations within our oral delivery solutions platform. These increases were partially offset by operational inefficiencies with respect to products utilizing our blow-fill-seal technology platform, ~~of 13%, increased volume from our biologics offerings of 6% and increased net revenue of 2%~~decreased profit from our analytical services platform driven by ~~increased~~decreased sales volumes related to fee-for-service development work and analytical testing in the U.S., and a reduction in profit related to product participation.

Drug Delivery Solutions' segment EBITDA increased by $22.2 million, or 56%, compared to the three months ended March 31, 2016, excluding the impact of foreign exchange, primarily due to an increase in sales volumes driven by favorable end customer demand for certain higher margin offerings primarily in our U.S. operations within our oral delivery solutions platform and increased volume from our biologics offerings, partially offset by reduced volume with respect to products utilizing our blow-fill-seal technology platform.

On September 22, 2016, we acquired Pharmatek Laboratories, Inc. ("Pharmatek"), a contract drug development and clinical manufacturing company, based in the U.S. Pharmatek adds discovery-to-clinic drug development capabilities, expands our capability for handling highly potent compounds, and adds spray drying to our portfolio of advanced delivery technologies. The net revenue and EBITDA impact to our Drug Delivery Solutions segment from the Catalent Indiana acquisition for the three months ended ~~March~~December 31, 2017 iswas an increase of 4%21% and 3%40%, respectively, as compared to the prior-year period.

Clinical Supply Services segment


	2017 vs. 2016				2017 vs. 2016
Factors Contributing to Year-Over-Year Change	Three Months Ended March 31,				Three Months Ended December 31,
	Net Revenue		Segment EBITDA		Net Revenue		Segment EBITDA
Organic revenue / Segment EBITDA	44	%	43	%
Revenue/Segment EBITDA without acquisitions					36	%	55	%
Impact of acquisitions	—	%	—	%	—	%	—	%
Constant currency change	44	%	43	%	36	%	55	%
Foreign currency translation impact on reporting	(8	)%	(13	)%	5	%	9	%
Total % Change	36	%	30	%	41	%	64	%

Clinical Supply Services' net revenue increased by ~~$31.4~~$28.0 million, or ~~44%~~36%, compared to the three months ended ~~March~~December 31, 2016, excluding the impact of foreign exchange, primarily due to increased lower-margin comparator sourcing volume of approximately ~~$15~~$17 million, or ~~21%. Revenue also increased, driven by~~22%, and higher volume ~~related to~~and favorable mix in our storage and distribution business of approximately $9$13 million, or ~~12%, and increased volume in our manufacturing and packaging business of approximately $7 million, or 11%~~16%.

Clinical Supply Services' segment EBITDA increased by ~~$5.2~~$6.4 million, or ~~43%~~55%, excluding the impact of foreign exchange, compared to the three months ended ~~March~~December 31, 2016, primarily due to increased sales volumes and favorable mix in our storage and distribution business, improved capacity utilization across the network, and ~~manufacturing and packaging businesses, as well as~~ increased profit from our lower-margin comparator sourcing.

3436

Table of Contents

~~Nine~~

Six Months Ended ~~March~~December 31, 2017 Compared to the ~~Nine~~Six Months Ended ~~March~~December 31, 2016


	Nine Months Ended March 31,					FX impact			Constant Currency Increase/(Decrease)				Six Months Ended December 31,						FX impact			Constant Currency Increase/(Decrease)
(Dollars in millions)	2017		2016						Change $		Change %		2017			2016						Change $			Change %
Net revenue	$	1,458.5	$	1,315.9		$	(40.6	)	$	183.2	14	%	$	1,150.2		$	925.9		$	23.5		$	200.8		22	%
Cost of sales	1,019.1		916.1			(22.7		)	125.7		14	%	822.7			653.9			18.8			150.0			23	%
Gross margin	439.4		399.8			(17.9		)	57.5		14	%	327.5			272.0			4.7			50.8			19	%
Selling, general and administrative expenses	295.3		268.6			(4.7		)	31.4		12	%	221.3			194.4			1.4			25.5			13	%
Impairment charges and (gain)/loss on sale of assets	2.3		0.8			—			1.5		*		4.2			0.5			0.1			3.6			*
Restructuring and other	4.5		3.4			0.3			0.8		24	%	1.3			4.4			—			(3.1		)	(70	)%
Operating earnings	137.3		127.0			(13.5		)	23.8		19	%	100.7			72.7			3.2			24.8			34	%
Interest expense, net	67.5		66.7			(2.1		)	2.9		4	%	51.5			44.9			0.3			6.3			14	%
Other (income)/expense, net	3.4		(7.1		)	(2.1		)	12.6		*		19.3			(3.9		)	2.3			20.9			*
Earnings from continuing operations, before income taxes	66.4		67.4			(9.3		)	8.3		12	%	29.9			31.7			0.6			(2.4		)	(8	)%
Income tax expense	18.4		14.3			(1.9		)	6.0		42	%
Net earnings	48.0		53.1			(7.4		)	2.3		4	%
Less: Net earnings/(loss) attributable to noncontrolling interest, net of tax	—		(0.3		)	—			0.3		*
Net earnings attributable to Catalent	$	48.0	$	53.4		$	(7.4	)	$	2.0	4	%
Income tax expense/(benefit)													48.0			9.7			(0.3		)	38.6			*
Net earnings/(loss)													$	(18.1	)	$	22.0		$	0.9		$	(41.0	)	*

*Percentage not meaningful

Net Revenue

Net revenue increased by ~~$183.2~~$200.8 million, or ~~14%~~22%, as compared to the ~~nine~~six months ended ~~March~~December 31, 2016, excluding the impact of foreign exchange. ~~The increase~~Net revenue increased 11% as a result of acquisitions. We acquired Pharmatek Laboratories, Inc. ("Pharmatek") in ~~net revenue was driven by higher sales across all three reportable segments, led by~~September 2016 and Catalent Indiana in October 2017, both within our Drug Delivery Solutions segment, and Accucaps in February 2017, within our Softgel Technologies ~~segments. The increase in~~segment. Excluding the impact of acquisitions, net revenue ~~was~~increased 11%, primarily due to increased volume ~~related to~~in lower-margin comparator sourcing and within our storage and distribution business within our Clinical Supply Services segment and favorable end customer demand for certain higher margin offerings within our oral delivery solutions platform and ~~favorable end customer demand for~~increased volume from our biologics offerings within our Drug Delivery Solutions ~~segment. In addition, net revenue increased due to end-market volume demand for~~segment in our higher margin prescription products in Europe within our Softgel Technologies segment compared to lower production levels related to the temporary suspension of operations in the prior fiscal year. We also acquired Pharmatek in September 2016 and Accucaps in February 2017, which increased net revenue within our Drug Delivery Solutions and our Softgel Technologies segments, respectively.U.S. operations.

Gross Margin

Gross margin increased by ~~$57.5~~$50.8 million, or ~~14%~~19%, as compared to the ~~nine~~six months ended ~~March~~December 31, 2016, excluding the impact of foreign ~~exchange,~~exchange. Gross margin increased across all three reportable segments primarily due to ~~increased~~increase sales volumes and favorable product mix within our oral delivery solutions platform and our biologics offering within our Drug Delivery Solutions segment, partially offset by the timing of the resolution of volume commitments in the prior year. Our Softgel Technologies segment also drove increased gross margin from increased volume and a favorable mix shift to higher margin prescription products.as discussed above. On a constant currency basis, gross margin, as a percentage of revenue, ~~increased 10~~decreased 70 basis points to ~~30.5%~~28.7% in the ~~nine~~six months ended ~~March~~December 31, 2017 as compared to ~~30.4%~~29.4% in the ~~prior year.~~prior-year period, primarily driven by decreased product participation revenue within both our Softgel Technologies and our Drug Delivery Solutions segments and an unfavorable mix shift within our Softgel Technologies segment to lower-margin consumer health products as a result of the Accucaps acquisition, partially offset by a favorable mix shift to certain higher margin offerings within our oral delivery solutions and biologics offerings in our U.S. operations within our Drug Delivery Solutions segment.

Selling, General and Administrative Expense

Selling, general and administrative expense increased ~~$31.4~~$25.5 million, or ~~12%~~13%, as compared to the ~~nine~~six months ended ~~March~~December 31, 2016, excluding the impact of foreign exchange, primarily ~~due~~driven by acquisition related expenses during the period, including one-time transaction fees of $10 million related to the acquisition of Catalent Indiana in October 2017 and an increase of approximately $11 million, which included approximately $6 million of incremental depreciation and amortization expense and $4 million incremental employee-related ~~costs of~~costs. Selling, general and administrative expenses further increased approximately ~~$24.0~~$4 million ~~of which approximately $7.8 million was attributable to an increase in our~~for non-cash equity-based compensation ~~plans. Other increases to employee-related cost included inflationary increases,~~driven by higher expense for certain employee retention, relocation and recruiting costs and health and wellness costs. Equity-based compensation expense increased as a result of a change from a cash-based long-term incentive plan to an equity-based long-term incentive plan, an acceleration of expense related to retirement-eligible employees and incremental expense related to stock options that vested upon achieving certain return on invested capital targets. In addition, selling, general and administrative expense increased approximately $14.0 million due to recently acquired companies, which included approximately $5.0 million of integration related costs, partiallyperformance based awards in the current period.

3537

Table of Contents

~~offset by a reduction~~Impairment charges and (gain)/loss on sale of assets

Impairment charges and loss on sale of assets of $4.2 million includes the loss on sale of two Softgel Technologies segment manufacturing sites in ~~expense of approximately $3.0 million related~~the Asia Pacific region. The site divestitures were material neither individually nor in aggregate to the ~~temporary suspension at our Beinheim facility. There was a further reduction in acquisition-related transaction costs of approximately $2.0 million compared~~segment or to the ~~prior year.~~Company.

Restructuring and Other

Restructuring and other charges of ~~$4.5~~$1.3 million for the ~~nine~~six months ended ~~March~~December 31, 2017 ~~increased~~decreased by ~~$1.1~~$3.1 million, compared to the ~~nine~~six months ended ~~March~~December 31, 2016. ~~The nine~~Other costs in the six months ended ~~March~~December 31, ~~2017~~2016 included ~~restructuring activities~~claim resolution charges of $3.2 million (without regard to ~~improve cost efficiency primarily~~possible future insurance recoveries), related to ~~employee severance expenses~~a previous temporary regulatory suspension at one of ~~$3.7 million offset with the recovery of previously recorded facility exit costs of $2.4 million associated with site closures completed in the previous year.~~our manufacturing facilities. Restructuring expense will vary period to period based on the level of acquisitions during the year and site consolidation efforts to further streamline the business. ~~Other costs included claim resolution charges of $3.2 million (without regard to possible future insurance recoveries), related to the temporary suspension at our Beinheim facility.~~

Interest Expense, net

Interest expense, net of ~~$67.5~~$51.5 million for the ~~nine~~six months ended ~~March~~December 31, 2017 increased ~~$0.8~~$6.6 million as compared to the ~~nine~~six months ended ~~March~~December 31, 2016, primarily driven by an average higher level of outstanding debt ~~resulting from~~associated with the ~~issuance of~~financing for the ~~Notes issued~~Catalent Indiana acquisition in ~~December 2014,~~October 2017, offset by principal payments on ~~Operating Company's~~our term loans and an overall reduction in ~~December 2016 in the~~our interest rates on ~~its~~our senior secured credit facility as compared to the prior year period.

On October 18, 2017, we completed the Debt Offering. Concurrent with the Debt Offering, we completed the Third Amendment, which lowered the interest rate on U.S. dollar-denominated and euro-denominated term loans and the revolving credit facility. The ~~net increase to our outstanding~~new applicable rate for U.S. dollar-denominated term loans decreased 0.50%, and the new applicable rate for euro-denominated term loans is LIBOR decreased 0.75%. The new applicable rate for the revolving loans decreased 1.25%.

Further, a component of the purchase price for the Catalent Indiana acquisition consists of $200 million in deferred purchase consideration payable in $50 million installments, on each anniversary of the closing date over a period of four years, which is accounted for as debt ~~balance is $164 million as compared to~~and includes a component of imputed interest expense.

On December 9, 2016, we completed the Euro Notes offering. The Euro Notes bear interest at the rate of 4.75% per annum and are payable semi-annually in arrears on June ~~30, 2016.~~15 and December 15 of each year.

Other (Income)/Expense, net

Other expense, net of ~~$3.4~~$19.3 million for the ~~nine~~six months ended ~~March~~December 31, 2017 was primarily driven by ~~$4.3~~$11.8 million of financing charges related to the ~~December 2016 private offering of the Notes~~Debt Offering and the ~~repricing~~Third Amendment and ~~partial paydown~~includes a $6.1 million charge for commitment fees paid during the first quarter of fiscal 2018 on the ~~senior secured credit facility, partially offset by~~Bridge Facility. Further, other expense, net for the six months ended December 31, 2017 includes $6.9 million of non-cash net ~~gains~~losses from foreign exchange ~~translation recorded during the period.~~ translation.

Other income, net for the ~~nine~~six months ended ~~March~~December 31, 2016 of ~~$7.1~~$3.9 million was primarily driven by non-cash net gains from foreign exchange translation recorded during the period of $7.5 ~~million.~~million, partially offset by $4.3 million of financing charges in the prior year.

Provision/(Benefit) for Income Taxes

During the second quarter ended December 31, 2017, we recorded a one-time net charge of $46.0 million within our income tax provision as a provisional estimate of the net accounting impact of the 2017 Tax Act in accordance with SAB 118, of which $48.7 million million related to the mandatory transition tax for deemed repatriation of deferred foreign income, $8.7 million of which we expect to pay over an 8-year period after considering the use of certain net operating losses and foreign tax credits, and certain limitations on executive compensation. The impact to our business resulting from the 2017 Tax Act, including related changes to our tax obligations and effective tax rate in future periods, as well as the one-time enactment-related charges recorded during the second quarter in fiscal 2018 on a provisional basis, are based on a reasonable estimate and are subject to change, and any change could differ materially from our current expectations. Further, there are certain effects of the 2017 Tax Act we cannot reasonably estimate as of the time of this filing, including (a) the GILTI rules, (b) the FDII deduction, (c) the BEAT, (d)provisions eliminating or reducing certain income tax deductions, such as interest expense, and certain employee expenses, and (e) the state tax impact of the 2017 Tax Act. As additional data is gathered, analyzed, and considered in context of the 2017 Tax Act and ASC 740, we may record additional or different tax charges in future periods during the measurement period.

Our provision for income taxes for the ~~nine~~six months ended ~~March~~December 31, 2017 was ~~$18.4~~$48.0 million relative to earnings before income taxes of ~~$66.4~~$29.9 million. Our provision for income taxes for the ~~nine~~six months ended ~~March~~December 31, 2016 was ~~$14.3~~ $9.7

Table of Contents

million relative to earnings before income taxes of ~~$67.4~~$31.7 million. The income tax provision for the current period is not comparable to the same period of the prior year due to the impact of the 2017 Tax Act, changes in pretax income over many jurisdictions, and the impact of discrete items. Generally, fluctuations in the effective tax rate are primarily due to changes in our geographic pretax income resulting from our business mix and changes in the tax impact of permanent differences, restructuring, other special items, and other discrete tax items, which may have unique tax implications depending on the nature of the item. ~~Our effective tax rate at March 31, 2017 reflects benefits derived from operations outside the United States, which are generally taxed at lower rates than the U.S. statutory rate of 35%.~~

~~Table of Contents~~

Segment Review

The Company’s results on a segment basis for the ~~nine~~six months ended ~~March~~December 31, 2017 compared to the ~~nine~~six months ended ~~March~~December 31, 2016 were as follows:


	Nine Months Ended March 31,						FX impact			Constant Currency Increase/(Decrease)					Six Months Ended December 31,						FX impact			Constant Currency Increase/(Decrease)
(Dollars in millions)	2017			2016						Change $			Change %		2017			2016						Change $			Change %
Softgel Technologies
Net revenue	$	598.2		$	550.2		$	(7.0	)	$	55.0		10	%	$	447.8		$	388.3		$	11.1		$	48.4		12	%
Segment EBITDA	125.3			104.8			(5.0		)	25.5			24	%	85.2			73.9			1.2			10.1			14	%
Drug Delivery Solutions
Net revenue	639.9			568.2			(17.4		)	89.1			16	%	511.2			405.3			9.5			96.4			24	%
Segment EBITDA	151.5			139.5			(7.5		)	19.5			14	%	128.5			92.0			2.3			34.2			37	%
Clinical Supply Services
Net revenue	249.5			226.0			(16.7		)	40.2			18	%	218.4			152.0			4.1			62.3			41	%
Segment EBITDA	37.8			39.5			(4.3		)	2.6			7	%	35.7			22.1			1.1			12.5			57	%
Inter-segment revenue elimination	(29.1		)	(28.5		)	0.5			(1.1		)	4	%	(27.2		)	(19.7		)	(1.2		)	(6.3		)	32	%
Unallocated Costs ⁽¹⁾	(72.9		)	(43.9		)	1.7			(30.7		)	70	%
Combined Total
Unallocated costs ⁽¹⁾															(82.2		)	(40.1		)	(2.3		)	(39.8		)	99	%
Combined total
Net revenue	$	1,458.5		$	1,315.9		$	(40.6	)	$	183.2		14	%	$	1,150.2		$	925.9		$	23.5		$	200.8		22	%

EBITDA from continuing operations	$	241.7		$	239.9		$	(15.1	)	$	16.9		7	%	$	167.2		$	147.9		$	2.3		$	17.0		11	%

*Percentage not meaningful


(1)	Unallocated costs includes equity-based compensation, certain acquisition-related costs, impairment charges, and certain ~~other corporate directed costs, certain customer claim expenses related to the temporary Beinheim facility suspension and~~ other costs that are not allocated to the segments as follows:


	Nine Months Ended March 31,						Six Months Ended December 31,
(Dollars in millions)	2017			2016			2017			2016
Impairment charges and gain/(loss) on sale of assets	$	(2.3	)	$	(0.8	)	$	(4.2	)	$	(0.5	)
Equity compensation	(16.4		)	(8.7		)	(15.5		)	(11.8		)
Restructuring and other special items ⁽²⁾	(21.6		)	(15.7		)	(24.2		)	(13.1		)
Noncontrolling interest	—			0.3
Other income/(expense), net ⁽³⁾	(3.4		)	7.1			(19.3		)	3.9
Non-allocated corporate costs, net	(29.2		)	(26.1		)	(19.0		)	(18.6		)
Total unallocated costs	$	(72.9	)	$	(43.9	)	$	(82.2	)	$	(40.1	)


(2)	~~Segment results do not~~Restructuring and other special items include ~~restructuring~~transaction and ~~other~~integration costs associated with ~~certain customer claim expenses related to~~ the ~~temporary Beinheim facility suspension and certain acquisition-related costs.~~


~~(3)~~	Amounts for the nine months ended March 31, 2017 primarily relate to the December 2016 refinancing activity, and amounts for the nine months ended March 31, 2016 primarily relate to foreign currency translation gains and losses.acquisition of Catalent Indiana.

3739

Table of Contents


(3)	Amounts for the six months ended December 31, 2017 include $11.8 million of financing expenses related to the offering of the USD Notes and the Third Amendment and include a $6.1 million charge for commitment fees paid during the first quarter of fiscal 2018 the Bridge Facility.

Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations:


	Nine Months Ended March 31,				Six Months Ended December 31,
(Dollars in millions)	2017		2016		2017			2016
Earnings from continuing operations	$	48.0	$	53.1
Earnings/(loss) from continuing operations					$	(18.1	)	$	22.0
Depreciation and amortization	107.8		105.5		85.8			71.3
Interest expense, net	67.5		66.7		51.5			44.9
Income tax (benefit)/expense	18.4		14.3		48.0			9.7
Noncontrolling interest	—		0.3
EBITDA from continuing operations	$	241.7	$	239.9	$	167.2		$	147.9

Softgel Technologies segment


	2017 vs. 2016				2017 vs. 2016
Factors Contributing to Year-Over-Year Change	Nine Months Ended March 31,				Six Months Ended December 31,
	Net Revenue		Segment EBITDA		Net Revenue		Segment EBITDA
Organic revenue / Segment EBITDA	8	%	21	%
Revenue/Segment EBITDA without acquisitions					(1	)%	1	%
Impact of acquisitions	2	%	3	%	13	%	13	%
Constant currency change	10	%	24	%	12	%	14	%
Foreign currency translation impact on reporting	(1	)%	(4	)%
Foreign exchange fluctuation					3	%	1	%
Total % Change	9	%	20	%	15	%	15	%

Softgel Technologies’ net revenue increased ~~$55~~$48.4 million, or ~~10%~~12%, excluding the impact of foreign exchange, compared to the six months ended December 31, 2016. Net revenue decreased 1%, excluding the impact of the Accucaps acquisition, primarily driven by decreased profit participation revenue of 1% as compared to ~~the nine~~six months ended ~~March~~December 31, 2016, primarily driven by increased end market volume demand for prescription products in Europe, which included increased volume at our Beinheim, France facility of approximately $20.0 million, compared to lower production levels related to a temporary suspension in the prior fiscal year. In addition, net revenue increased as a result of higher end-market volume demand for prescription products in North America, partially offset by lower end-market volume demand for consumer health products in Asia Pacific.2016.

Softgel Technologies' Segment EBITDA increased by ~~$25.5~~$10.1 million, or ~~24%~~14%, as compared to the ~~nine~~six months ended ~~March~~December 31, 2016, excluding the impact of foreign ~~exchange,~~exchange. Segment EBITDA increased 1% excluding the impact of the Accucaps acquisition. Excluding the reduction of product participation profit of 5%, segment EBITDA without acquisitions increased 6%, primarily ~~driven by~~related to the impact of a historical contractual settlement of 4% and a favorable shift in product mix ~~shift to~~within our prescription products increased volume and reduced one-time suspension-related cost at our Beinheim facility of approximately $9.0 million. Refer to Note 12 to the unaudited consolidated financial statements included elsewhere in ~~this Quarterly Report on Form 10-Q for further discussion.~~North America.

Net revenue and Segment EBITDA in our Softgel Technologies segment increased in the ~~nine~~six months ended ~~March~~December 31, 2017 compared to the ~~nine~~six months ended ~~March~~December 31, 2016 by 2%13% and 3%13%, respectively, due to the Accucaps acquisition.

~~Drug Delivery Solutions segment~~

2017 vs. 2016
Factors Contributing to Year-Over-Year Change Nine Months Ended
March 31,
Net Revenue Segment EBITDA
Organic revenue / Segment EBITDA 13 % 13 %
Impact of acquisitions 3 % 1 %
Constant currency change 16 % 14 %
Foreign currency translation impact on reporting (3 )% (5 )%
Total % Change 13 % 9 %

3840

Table of Contents

Drug Delivery Solutions segment



	2017 vs. 2016
Factors Contributing to Year-Over-Year Change	Six Months Ended December 31,
	Net Revenue		Segment EBITDA
Revenue/Segment EBITDA without acquisitions	11	%	14	%
Impact of acquisitions	13	%	23	%
Constant currency change	24	%	37	%
Foreign exchange fluctuation	2	%	3	%
Total % Change	26	%	40	%

Net revenue in our Drug Delivery Solutions segment increased by ~~$89.1~~$96.4 million, or ~~16%~~24%, as compared to the ~~nine~~six months ended ~~March~~December 31, 2016, excluding the impact of foreign exchange. ~~Excluding the impact of the resolution of volume commitments of $12.5 million in the prior year, organic net revenue~~Revenue without acquisitions increased by ~~15%~~11%, driven primarily by favorable end customer demand for certain higher margin offerings primarily in our U.S. operations within our oral delivery solutions platform of 8%5%,increased volume from our biologics offerings of 5%4% and by timing of execution related to timing of a standard maintenance shut-down at our European sterile pre-filled syringe facility of 2%.

Drug Delivery Solutions' Segment EBITDA increased by $34.2 million, or 37%, compared to the six months ended December 31, 2016, excluding the impact of foreign exchange. Segment EBITDA without acquisitions increased by 14%, primarily due to an increase in sales volumes driven by favorable end-customer demand for certain higher margin offerings primarily in our U.S. operations within our oral delivery solutions platform of 11%, increased volume from our biologics offerings of 10%, and favorable absorption of cost and timing of a standard maintenance shut-down at our European sterile pre-filled syringe facility of 5%. Segment EBITDA also increased ~~volume~~as a result of increased profit from our San Diego site (obtained as part of the Pharmatek acquisition) lapping a full year of ownership. These increases were partially offset by operational inefficiencies with respect to products utilizing our blow-fill-seal technology platform of 10%, decreased profit from our analytical services platform ~~of 2%~~ driven by ~~increased~~decreased sales volumes related to fee-for-service development work and analytical testing in the U.S. of 6%.

~~Drug Delivery Solutions' Segment EBITDA increased by $19.5 million, or 14%, as compared to the nine months ended March 31,~~On September 22, 2016, excluding the impact of foreign exchange, primarily due to the timing of the resolution of volume commitments of $12.5 million in the prior year. Excluding this event, Segment EBITDA increased $29.9 million, or 24%, primarily due to increased volumes within our biologics offering, increased volumes and favorable product mix within our analytical services platform and increased volumes related to our integrated oral solids development and manufacturing capabilities within our oral delivery solutions platform.

~~Our acquisition of~~we acquired Pharmatek, which increased net revenue and EBITDA in our Drug Delivery Solutions segment for the ~~nine~~six months ended ~~March~~December 31, 2017 by 3%2% and 1%, respectively, ascompared to the corresponding prior-year period.

On October 23, 2017, we acquired Catalent Indiana which increased net revenue and EBITDA in our Drug Delivery Solutions segment for the six months ended December 31, 2017 by 11% and 22%, respectively, compared to the corresponding prior-year period.

Clinical Supply Services segment


	2017 vs. 2016				2017 vs. 2016
Factors Contributing to Year-Over-Year Change	Nine Months Ended March 31,				Six Months Ended December 31,
	Net Revenue		Segment EBITDA		Net Revenue		Segment EBITDA
Organic revenue / Segment EBITDA	18	%	7	%
Revenue/Segment EBITDA without acquisitions					41	%	57	%
Impact of acquisitions	—	%	—	%	—	%	—	%
Constant currency change	18	%	7	%	41	%	57	%
Foreign currency translation impact on reporting	(8	)%	(11	)%
Foreign exchange fluctuation					3	%	5	%
Total % Change	10	%	(4	)%	44	%	62	%

Clinical Supply Services' net revenue increased by ~~$40.2~~$62.3 million, or ~~18%~~41%, as compared to the ~~nine~~six months ended ~~March~~December 31, 2016, excluding the impact of foreign exchange, primarily due to increased lower-margin comparator sourcing volume of approximately $35 million, or 23%, and higher volume related to our storage and distribution business of approximately ~~$17~~$27 million, or ~~7%, increased lower-margin comparator sourcing volume of approximately $14 million, or 6%, and increased volume in our manufacturing and packaging business of approximately $9 million, or 4%~~18%.

Clinical Supply Services' Segment EBITDA increased by ~~$2.6~~$12.5 million, or 7%57%, excluding the impact of foreign exchange, as compared to the ~~nine~~six months ended ~~March~~December 31, 2016, primarily due to increased sales volumes in our storage and

Table of Contents

distribution ~~and manufacturing and packaging businesses,~~business, improved capacity utilization across the network, as well as increased profit from our lower-margin comparator sourcing.

Liquidity and Capital Resources

Sources and Uses of Cash

Our principal source of liquidity has been cash flows generated from ~~operations.~~operations and certain financing activities for acquisitions. The principal uses of cash are to fund planned operating and capital expenditures, business or asset acquisitions, interest payments on debt and any mandatory or discretionary principal payments on debt issuances. ~~In the second quarter of fiscal 2017, cash available for general corporate purposes increased as a result of Operating Company's offering of the Notes.~~ As of ~~March~~December 31, 2017, our financing needs were supported by the five-year, $200 million ~~of available funds under Operating Company's~~ revolving credit facility maintained by Catalent Pharma Solutions, Inc. (our "Operating Company") that matures in May 2022 (following the Third Amendment in October 2017), the capacity of which ~~was~~is reduced by $13.0 million ofin outstanding letters of credit. The revolving credit facility ~~matures in May 2019.~~includes borrowing capacity available for letters of credit and for short-term borrowings, referred to as swing-line borrowings. As of December 31, 2017, we had no outstanding borrowings under our revolving credit facility.

On October 29, 2015, our Board of Directors authorized a share repurchase program to use up to $100.0 million to repurchase shares of our outstanding common stock. Under the program, we are authorized to repurchase shares through open market purchases, privately negotiated transactions or otherwise as permitted by applicable federal securities laws. There has been no purchase pursuant to this program as of ~~March~~December 31, 2017.

~~Table of Contents~~U.S. Tax Reform Considerations

Recent changes to the taxation of undistributed foreign earnings in connection with the 2017 Tax Act could potentially change our future intentions regarding the reinvestment of such earnings. We intend to continue to monitor regulatory developments concerning the taxation of undistributed foreign earnings, as well as our liquidity needs both domestic and foreign. If our plans change and we choose to repatriate any funds to the U.S. in the future, we could potentially be subject to applicable state, local, and/or foreign taxes. We have yet to determine the potential use of any cash that may be repatriated to the U.S. as a result of the 2017 Tax Act. Based on the current estimate of the mandatory transition cash tax liability of $8.7 million and timing of the related payments, we believe that cash from operations will be sufficient to make all required payments.

Cash Flows

The following table summarizes our consolidated statement of cash ~~flows from continuing operations:~~flows:


	Nine Months Ended March 31,									Six Months Ended December 31,
(Dollars in millions)	2017			2016			Difference			2017			2016			Difference
Net cash provided by/(used in):
Operating activities	$	199.3		$	121.4		$	77.9		$	176.0		$	96.0		$	80.0
Investing activities	$	(257.0	)	$	(107.8	)	$	(149.2	)	$	(825.7	)	$	(138.5	)	$	(687.2	)
Financing activities	$	168.4		$	(27.1	)	$	195.5		$	682.4		$	175.7		$	506.7

Operating Activities

For the ~~nine~~six months ended ~~March~~December 31, 2017, cash provided by operating activities was $~~199.3~~176.0 million compared to ~~$121.4~~$96.0 million for the corresponding prior-year ~~period,~~period. Cash flow from operating activities for the six months ended December 31, 2017 increased due to certain working capital improvements primarily driven by ~~favorable working capital changes.~~a decrease in trade receivables from the higher collection of receivables during the current-year six-month period compared to the prior-year period.

Investing Activities

For the ~~nine~~six months ended ~~March~~December 31, 2017, cash used in investing activities was $~~257.0~~825.7 million compared to $~~107.8~~138.5 million for the ~~nine~~six months ended ~~March~~December 31, 2016, primarily driven by ~~$169.9~~$748.0 million of cash paid for the acquisition of Catalent Indiana in the second quarter of fiscal 2018. During the prior-year six-month period, $86.9 million of cash was paid for the acquisition of Pharmatek, ~~and Accucaps,~~ net of cash ~~acquired,~~acquired. The increase in ~~the 2017 period. There~~cash used in investing activities was ~~no completed acquisition in fiscal 2016. The current year acquisition activity was partially offset by a decrease~~also due to an increase in acquisitions of property, plant and equipment, which totaled $~~87.8~~82.9 million for the ~~nine~~six months ended ~~March~~December 31, 2017 compared to $~~107.8~~54.1 million in the ~~nine~~six months ended ~~March~~December 31, 2016.

Table of Contents

Financing Activities

For the ~~nine~~six months ended ~~March~~December 31, 2017, cash provided by financing activities was $~~168.4~~682.4 million compared to ~~cash used in financing activities of~~ $~~27.1~~175.7 million for the ~~nine~~six months ended ~~March~~December 31, 2016, primarily driven by net proceeds of ~~$397.4~~$442.6 million ~~from~~and $277.8 million raised as part of our Debt Offering and a primary offering of our common stock in September 2017 (the "Equity Offering"), respectively, during the ~~Notes~~current-year six-month period. In the Equity Offering, we sold 7.4 million shares of our common stock at a price of $39.10 per share, before underwriting discounts and commissions. The net proceeds of $277.8 million includes the effect of these discounts and commissions and other offering ~~in December 2016.~~expenses. The ~~Notes~~net proceeds of these offerings were used to repay $200 million of outstanding borrowings on the U.S. dollar denominated term loan, pay the $81.0 million then outstanding under the revolving credit facility during the second quarter, pay accrued and unpaid interest and certain fees and expenses associated with the offering, fund a ~~previously announced pending acquisition,~~portion of the initial consideration for the Catalent Indiana acquisition. Contemporaneous to completing the Debt Offerings, we completed the Third Amendment to lower the interest rate and ~~provide cash for general corporate purposes.~~extend the maturity dates on our senior secured credit facilities. In connection with the ~~Notes offering~~Debt Offering and ~~subsequent partial paydown~~the Third Amendment, we incurred $22.8 million of ~~the U.S. dollar-denominated term loan, the Company incurred $6.9 million of~~debt discount and third-party financing costs, of which ~~$0.6~~$11.8 million was expensed and ~~a $2.0 million expense related to unamortized debt discount and deferred financing costs respectively, both~~ recorded in ~~Other (Income) / Expense,~~other expense/(income), net in the consolidated statement of operations.

Guarantees and Security

Senior Secured Credit Facilities

All obligations under ~~Operating Company's term loan and revolving credit facilities (as amended,~~ the ~~“Credit Agreement”)~~Credit Agreement and the guarantees of those obligations are secured by substantially all of the following assets of Operating Company and each guarantor (Operating Company's parent entity, PTS Intermediate Holdings LLC ("PTS Intermediate"), and each of Operating Company's material domestic subsidiaries), subject to certain exceptions:

a pledge of 100% of the capital stock of ~~the borrower~~Operating Company and 100% of the equity interests directly held by ~~the borrower~~Operating Company and each guarantor in any wholly owned material subsidiary of ~~the borrower~~Operating Company or any guarantor (which pledge, in the case of any non-U.S. subsidiary of a U.S. subsidiary, will not include more than 65% of the voting stock of such non-U.S. subsidiary); and

a security interest in, and mortgages on, substantially all tangible and intangible assets of ~~the borrower~~Operating Company and of each guarantor, subject to certain limited exceptions.

~~Table of Contents~~

~~4.75% Senior~~The Euro Notes ~~Due 2024~~and the USD Notes

All obligations under the Euro Notes and the USD Notes are general, unsecured and subordinated to all existing and future secured indebtedness of the guarantors to the extent of the value of the ~~asset~~assets securing such indebtedness. The Euro Notes and the USD Notes are each separately guaranteed by all of Operating Company's wholly owned U.S. subsidiaries that guarantee the senior secured credit facilities. ~~The~~Neither the Euro Notes nor the USD Notes are ~~not~~ guaranteed by either PTS Intermediate ~~Holdings~~ or ~~Catalent.~~Catalent, Inc.

Debt Covenants

Senior Secured Credit Facilities

The Credit Agreement contains a number of covenants that, among other things, restrict, subject to certain exceptions, Operating Company’s (and Operating Company’s restricted subsidiaries’) ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; enter into sale and leaseback ~~transactions,~~transactions; amend material agreements governing Operating Company’s subordinated indebtedness and change Operating Company’s lines of business.

The Credit Agreement also contains change of control provisions and certain customary affirmative covenants and events of default. The revolving credit facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of ~~March~~December 31, 2017, we were in compliance with all material covenants related to our senior-secured obligations.

Subject to certain exceptions, the Credit Agreement permits us and our restricted subsidiaries to incur certain additional indebtedness, including secured indebtedness. None of our non-U.S. subsidiaries or Puerto Rico subsidiaries is a guarantor of the loans.

As market conditions warrant, we and our affiliates may from time to time seek to purchase our outstanding debt in privately negotiated or open market transactions, by tender offer or otherwise. Subject to any applicable limitation contained in the Credit Agreement, any purchase made by us may be funded by the use of cash on our balance sheet or the incurrence of new secured or unsecured debt. The amounts involved in any such purchase transactions, individually or in the aggregate, may be material. Any such purchase may be with respect to a substantial amount of a particular class or series of debt, with the

Table of Contents

attendant reduction in the trading liquidity of such class or series. In addition, any such purchases made at prices below the “adjusted issue price” (as defined for U.S. federal income tax purposes) may result in taxable cancellation of indebtedness income to us, which amounts may be material, and in related adverse tax consequences to us.

~~4.75% Senior~~The Euro Notes ~~Due 2024~~and the USD Notes

The ~~Indenture~~Indentures governing the Euro Notes ~~contains~~and the USD Notes (the "Indentures") contain covenants that, among other things, limit the ability of Operating Company and its restricted subsidiaries to incur or guarantee more debt or issue certain preferred shares, pay dividends on, repurchase or make distributions in respect of their capital stock or make other restricted payments, make certain investments, sell certain assets, create liens, consolidate, merge, sell or otherwise dispose of all or substantially all of their assets, enter into certain transactions with their affiliates, and designate their subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions, limitations and qualifications as set forth in the ~~Indenture.~~Indentures. The ~~Indenture~~Indentures also ~~contains~~contain customary events of default including, but not limited to, nonpayment, breach of covenants, and payment or acceleration defaults in certain other indebtedness of Operating Company or certain of its subsidiaries. ~~Upon~~Under the Indentures, upon an event of default, either the holders of at least 30% in principal amount of either the then-outstanding Euro Notes or the ~~Trustee~~then-outstanding USD Notes, or either of the Trustees under the applicable notes may declare the ~~Notes~~applicable notes immediately due and payable, or in certain circumstances, the ~~Notes~~applicable notes automatically will become due and immediately payable. As of ~~March~~December 31, 2017, we were in compliance with all material covenants related to the ~~Notes obligations.~~Indentures.

As of ~~March~~December 31, 2017 and June 30, ~~2016~~2017, the amounts of cash and cash equivalents held by foreign subsidiaries were ~~$210.7~~$272.2 million and ~~$129.1~~$249.8 million, respectively, out of the total consolidated cash and cash equivalents of ~~$241.2~~$329.5 million and ~~$131.6~~$288.3 million, respectively. These balances are dispersed across many international locations around the world. It is our intention to indefinitely reinvest undistributed earnings of our foreign legal entities. In the event we needed to repatriate funds from outside U.S., such repatriation will be subject to tax consequences including foreign withholding taxes or U.S. income taxes. Our intent is to continue to reinvest undistributed earnings of our foreign local entities and we do not currently plan to repatriate them to fund our operations in the United States. In the event we need to repatriate funds from outside of the U.S., such repatriation would likely be subject to restrictions by local laws and/or tax consequences, including foreign withholding taxes or U.S. income taxes. It is not feasible to estimate the amount of U.S. tax that might be payable on the remittance of such earnings.

~~Table of Contents~~

Backlog

While we generally have long-term supply agreements that provide for a revenue stream over a period of years, our backlog represents, as of a point in time, future service revenues from work not yet completed. For our Softgel Technologies and Drug Delivery Solutions segments, backlog represents firm orders for manufacturing services and includes minimum volumes, where applicable. For our Clinical Supply Services segment, backlog represents estimated future service revenues from work not yet completed under signed contracts. Using these methods of reporting backlog, as of ~~March~~December 31, 2017, backlog was approximately ~~$1,020.4~~$1,121.6 million, compared to approximately ~~$827.5~~$1,052.2 million as of June 30, ~~2016,~~2017, including approximately ~~$329.8~~$306.0 million and ~~$292.1~~$338.3 million, respectively, related to our Clinical Supply Services segment. We expect to recognize approximately ~~56%~~70% of revenue from the backlog in existence as of ~~March~~December 31, 2017 by June 30, ~~2017.~~2018.

To the extent projects are delayed, the timing of our revenue could be affected. If a customer cancels an order, we may be reimbursed for the costs we have incurred. For orders that are placed inside a contractual firm period, we generally have a contractual right to payment in the event of cancellation. Fluctuations in our reported backlog levels also result from the timing and order pattern of our customers who often seek to manage their level of inventory on hand. Because of customer ordering patterns, our backlog reported for certain periods may fluctuate and may not be indicative of future results.

Interest Rate Risk Management

A portion of the debt used to finance our operations is exposed to interest-rate fluctuations. We may use various hedging strategies and derivative financial instruments to create an appropriate mix of ~~fixed-and~~fixed- and floating-rate assets and liabilities. Historically, we have used interest-rate swaps to manage the economic effect of variable rate interest obligations associated with our floating-rate term loans so that the interest payable on the term loans effectively becomes fixed at a certain rate, thereby reducing the impact of future interest-rate changes on our future interest expense. As of ~~March~~December 31, 2017, we did not have any interest-rate swap agreements in place that would have the economic effect of modifying the variable interest obligations associated with our floating-rate term loans.

Currency Risk Management

We are exposed to fluctuations in the ~~EUR-USD~~Euro-USD exchange rate on our investments in our operations in Europe. While we do not actively hedge against changes in foreign currency, we have mitigated the exposure of our investments in our European operations by denominating a portion of our debt in euros. At ~~March~~December 31, 2017, we had ~~$744.0~~$811.9 million of euro-denominated debt outstanding that qualifies as a hedge of a net investment in foreign operations. Refer to Note 89 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for further discussion of net investment hedge activity in the period.

Periodically, we may utilize forward currency exchange contracts to manage our exposure to the variability of cash flows primarily related to the foreign exchange rate changes of future foreign currency transaction costs. In addition, we may utilize

Table of Contents

foreign currency forward contracts to protect the value of existing foreign currency assets and liabilities. Currently, we do not utilize foreign currency exchange contracts. We expect to continue to evaluate hedging opportunities for foreign currency in the future.

Contractual Obligations

Besides the changes in our long-term obligations related to ~~our debt facilities and~~the Third Amendment, the offering of the USD Notes, and the deferred purchase consideration associated with the Catalent Indiana acquisition as disclosed in Liquidity and Capital Resources earlier in this Item, there has been no significant change to our contractual obligations since our Annual Report on Form 10-K for the period ended June 30, ~~2016.~~2017. Refer to Note 10 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a further discussion regarding tax reform and the Company's long-term obligations.

Off-Balance Sheet Arrangements

Other than operating leases and outstanding letters of credit as discussed above, we do not have any material off-balance sheet arrangements as of ~~March~~December 31, 2017.

4245

Table of Contents


Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to changes in interest rates associated with our long-term debt obligations and foreign exchange rate changes.

Interest Rate Risk

The Company has historically used interest-rate swaps to manage the economic effect of variable rate interest obligations associated with our floating-rate term loans so that the interest payable on the term loans effectively becomes fixed at a certain rate, thereby reducing the impact of future interest-rate changes on our future interest expense. As of ~~March~~December 31, 2017, we did not have any interest-rate swap agreements in place that would either have the economic effect of modifying the variable interest obligations associated with our floating-rate term loans or would be considered an effective cash flow hedge for financial reporting purposes.

Foreign Currency Exchange Risk

By the nature of our global operations, we are exposed to cash flow and earnings fluctuations resulting from foreign exchange rate variation. These exposures are transactional and translational in nature. Since we manufacture and sell our products throughout the world, our foreign currency risk is diversified. Principal drivers of this diversified foreign exchange exposure include the European euro, British pound, Argentinean peso, Brazilian real and Australian dollar. Our transactional exposure arises from the purchase and sale of goods and services in currencies other than the functional currency of our operational units. We also have exposure related to the translation of financial statements of our foreign subsidiaries into U.S. dollars, the functional currency of the parent. The financial statements of our operations outside the U.S. are measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign operations in U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. Foreign currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the statements of operations in “other (income)/expense, net.” Such foreign currency transaction gains and losses include inter-company loans denominated in non-U.S. dollar currencies.

4346

Table of Contents


Item 4.	CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer and our Executive Vice President and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any control or procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Our management, with the participation of our President and Chief Executive Officer, and our Executive Vice President and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our President and Chief Executive Officer and our Executive Vice President and Chief Financial Officer concluded that, as of ~~March~~December 31, 2017, our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

4447

Table of Contents

PART II. OTHER INFORMATION


Item 1.	LEGAL PROCEEDINGS

During the period November 2015 through April 2016, the primary French drug regulatory agency temporarily suspended operations at the Company’s softgel manufacturing facility in Beinheim, France, subject to exemptions for certain types of operations, and theThe Company continues to receive and resolve claims stemming ~~therefrom.~~from a prior, temporary, regulatory suspension of one of our manufacturing facilities. To date, more than 2530 customers of the facility have presented claims against the Company for alleged losses, including lost profits and other types of indirect or consequential damages that they have allegedly suffered due to the temporary suspension, or have reserved their right to do so subsequently. The Company is unable to estimate at this time either the total value of claims that are reasonably possible to be asserted with respect to this matter or the likely cost to resolve them, although (a) as of the end of ~~the third quarter of fiscal~~December 31, 2017, the Company recorded $3.2 million for claim amounts that the Company deemed to be both probable and reasonably estimable but is not currently in a position to record under GAAP any insurance recovery with respect to such costshas settled 18 customer claims and (b) certain remaining customers have presented the Company with support for other claims having an aggregate claim value of approximately ~~$37~~$4 million. ~~It is noteworthy that, to~~To date, none of the asserted claims takes into account limitations of liability in the contracts governing these claims or any other defense that the Company may assert. In addition, the Company may have insurance for additional costs it may incur as a result of such claims, subject to various deductibles and other limitations, but there can be no assurance as to the aggregate amount or timing of insurance recoveries against any such costs. ~~Changes to the operations of the Beinheim facility to address the issues leading to the suspension have increased the cost and therefore may affect the profitability of its operation.~~


Item 1A.	RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, ~~2016~~2017, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. ~~There~~Other than what was disclosed in the Special Note Regarding Forward-Looking Statements and discussed below, there has been no material change to the risk factors disclosed in the Company’s Annual Report on Form 10-K.

The following information amends, updates, and should be read in conjunction with the risk factors and information disclosed in the Fiscal 2017 10-K.

The impact to our business of recently enacted U.S. tax legislation could differ materially from our current estimates.

On December 22, 2017, the U.S. government enacted wide-ranging tax legislation, the 2017 Tax Act. The 2017 Tax Act significantly revises U.S. tax law by, among other provisions, lowering the applicable U.S. federal statutory income tax rate from 35% to 21%, creating a partial territorial tax system that includes a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions.

Although we are still determining whether the 2017 Tax Act will ultimately benefit our results of operations and financial condition in future periods, primarily by reducing the applicable U.S. federal statutory income tax rate from 35% to 21%, we recorded a one-time net charge of $46.0 million within our income tax provision as a provisional estimate of the net accounting impact of the 2017 Tax Act in the second quarter of fiscal 2018. We recorded this charge on a provisional basis, based on our present understanding of the 2017 Tax Act and other information available as of the time of the estimates, including assumptions and expectations about future events.

Although we believe these provisional amounts represent a reasonable estimate of the ultimate enactment-related impact the 2017 Tax Act will have on our consolidated financial statements, we may adjust these amounts materially as additional information becomes available and we complete further analyses. The impact of the 2017 Tax Act to our business in future

Table of Contents

periods is also subject to a variety of factors beyond our control including, but not limited to, (i) potential amendments to the 2017 Tax Act; (ii) potential changes to state, local, and foreign tax laws in response to the 2017 Tax Act; and (iii) potential new or interpretative guidance issued by the SEC, the Financial Accounting Standards Board or the Internal Revenue Service related to the 2017 Tax Act. Any of these factors could cause our actual results to differ materiality from our current expectations and/or investors’ expectations. Further, there are certain effects of the 2017 Tax Act we cannot reasonably estimate, including (a) the GILTI rules, (b) the FDII deduction, (c) the BEAT, (d) provisions eliminating or reducing certain income tax deductions, such as interest expense, and certain employee expenses, and (e) the state tax impact of the 2017 Tax Act. As we gather, analyze, and consider additional data in the context of the 2017 Tax Act and ASC 740 Income Taxes, we may adjust in future periods our current estimates, but we will do so only during the measurement period prescribed by SAB 118. Any such adjustment may be material.


Item 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Purchase of Equity Securities

None.


Item 3.	DEFAULTS UPON SENIOR SECURITIES

None.


Item 4.	MINE SAFETY DISCLOSURES

Not applicable.

~~Table of Contents~~


Item 5.	OTHER INFORMATION

Not applicable.


~~Item 6.~~	~~EXHIBITS~~

Item 6. EXHIBITS

Exhibits:



10.1		Offer letter, dated January 31, 2018, between Wetteny Joseph and Catalent Pharma Solutions, LLC (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed on February 5, 2018, File No. 001-36587) †

31.1		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended*

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended*

32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

101.1		The following financial information from Catalent, Inc.’s Quarterly Report on Form 10-Q for the quarter ended ~~March~~December 31, 2017 formatted in XBRL: (i) Consolidated Statements of Operations for the Three and Nine Months Ended ~~March~~December 31, 2017 and 2016; (ii) Consolidated Statements of Comprehensive Income/(Loss) for the Three and Nine Months Ended ~~March~~December 31, 2017 and 2016 (iii) Consolidated Balance Sheets as of ~~March~~December 31, 2017 and June 30, ~~2016;~~2017; (iv) Consolidated Statement of Changes in Shareholders’ Equity/(Deficit) as of ~~March~~December 31, 2017; (v) Consolidated Statements of Cash Flows for the ~~None~~Six Months Ended ~~March~~December 31, 2017 and 2016; and (vi) Notes to Unaudited Consolidated Financial Statements.


*	~~Filed herewith~~


**	~~Furnished herewith.~~

* Filed herewith

** Furnished herewith

† Represents a management contract, compensatory plan or arrangement in which the directors and/or executive officers are eligible to participate.

4649

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



		CATALENT, INC. (Registrant)

Date:	~~May 4, 2017~~February 5, 2018	By:	/s/ John R. Chiminski
			John R. Chiminski
			President & Chief Executive Officer

Date:	~~May 4, 2017~~February 5, 2018	By:	/s/ Matthew M. Walsh
			Matthew M. Walsh
			Executive Vice President & Chief Financial Officer

4750



	Three Months Ended				Nine Months Ended
	March 31, 2016				March 31, 2016
(Dollars in millions, except per share amounts)	As Reported		As Adjusted		As Reported		As Adjusted
Selling, general and administrative expenses	$	93.2	$	93.4	$	268.4	$	268.6
Earnings from continuing operations before income taxes	14.0		13.8		67.6		67.4
Income tax expense/(benefit)	4.2		3.1		$	18.3	$	14.3
Net earnings	9.8		10.7		49.3		53.1
Net earnings attributable to Catalent	$	9.8	$	10.7	$	49.6	$	53.4


Earnings per share attributable to Catalent:
Basic
Net earnings	0.08		0.09		0.40		0.43
Diluted
Net earnings	0.08		0.09		0.39		0.42



(Dollars in millions)
Balance at June 30, 2016	$	61.5
Additions for tax positions of current year	1.6
Reductions for tax positions of prior years	(1.4		)
Lapse of the applicable statute of limitations	(0.2		)
Balance at March 31, 2017	$	61.5